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Background – The genus Malassezia is comprised of a group of lipophilic yeasts that have evolved as skin 
commensals and opportunistic cutaneous pathogens of a variety of mammals and birds.  
Objectives – The objective of this document is to provide the veterinary community and other interested 
parties with current information on the ecology, pathophysiology, diagnosis, treatment and prevention of 
skin diseases associated with Malassezia yeasts in dogs and cats.  
Methods – The authors served as a Guideline Panel (GP) and reviewed the literature available prior to 
October 2018. The GP prepared a detailed literature review and made recommendations on selected topics. 
The World Association of Veterinary Dermatology (WAVD) Clinical Consensus Guideline committee provided 
guidance and oversight for this process. The document was presented at two international meetings of 
veterinary dermatology societies and one international mycology workshop; it was made available for 
comment on the WAVD website for a period of six months. Comments were shared with the GP electronically 
and responses incorporated into the final document.  
Conclusions and clinical importance – There has been a remarkable expansion of knowledge on 
Malassezia yeasts and their role in animal disease, particularly since the early 1990’s. Malassezia dermatitis 
in dogs and cats has evolved from a disease of obscurity and controversy on its existence, to now being a 
routine diagnosis in general veterinary practice. Clinical signs are well-recognised and diagnostic approaches 
are well-developed. A range of topical and systemic therapies is known to be effective, especially when 
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Synopsis of the Clinical Consensus Guidelines. 
 
1. Introduction 
This section summarises the main conclusions from each of the section of the Consensus Guidelines. 
Literature reviews underpinning each of these summaries and recommendations are presented in the full 
text version.  
 
2. The Genus Malassezia 
Malassezia yeasts are unique in several ways, including their strict dependence on lipids, their cellular 
ultrastructure, and their dominance as eukaryotic residents on the skin of warm-blooded vertebrates. The 
taxonomy of the genus Malassezia is evolving. Eighteen species have been described to date but many other 
species are most probably present on the skin or mucosal sites of warm-blooded animals. Few phenotypic 
tests are available to differentiate Malassezia species and some of them may overlap. Consequently, DNA 
sequencing (or other techniques such as mass spectrometry) may be required for specific identification. 
 
3. Historical aspects  
The history of the association between Malassezia yeasts and their animal hosts has been long-mired in 
controversy. Having been previously overlooked, canine Malassezia dermatitis has evolved from a 
controversial to a now routine diagnosis in small animal practice, with very significant welfare benefits for 
many animals.  
 
4. Ecology and epidemiology 
Malassezia pachydermatis is a normal inhabitant of healthy canine skin and mucosae; it also predominates 
on the skin of the domestic cat, although other species are occasionally identified, particularly M. nana in 
the ear canal and M. slooffiae in the claw fold. Population sizes vary markedly between anatomical sites and 
between different breeds. These commensal Malassezia populations provide a reservoir of yeasts that might 
proliferate and or induce an inflammatory response under the influence of various host predisposing factors.  
 
5. Pathogenesis: virulence attributes amongst Malassezia yeasts 
There have been significant advances in understanding of the mechanisms of interaction between Malassezia 
yeasts and their hosts. The outcome of Malassezia growth in the stratum corneum is dependent upon the 
metabolic activities of the yeasts (expression of cell wall and secreted virulence attributes) and the host’s 
innate and adaptive immune defensive responses; interactions with other skin commensals (especially 
staphylococci) may also play a role. All these processes should ideally result in a delicately balanced 
homeostatic relationship. Further studies are required to define fully the parameters that dictate transitions 
between commensalism and parasitism that may yield opportunities for novel preventative and therapeutic 
strategies.  
 
6. Pathogenesis: immunological responses to Malassezia yeasts and their clinical relevance in 
diagnosis/therapy 
A range of immunological hyper-responsiveness can be present in dogs with Malassezia dermatitis (none, 
immediate, delayed, contact). Tests for immediate hypersensitivity (serology, intradermal) are relatively 
accessible (although not standardised) whereas delayed reactivity following intradermal testing is assessed 
infrequently and patch testing is technically challenging in the clinical environment.  
 
Serological and skin test reactivity is also seen in a proportion of unaffected dogs; thus immunological tests 
must be assessed in the context of clinical and cytological data; they should not be used as stand-alone 
‘diagnostic’ tests.  
 
It is intuitive that evidence of immediate, IgE-mediated or cellular hypersensitivity might indicate the need 
for rigorous antifungal therapy to minimize allergen challenge in the sensitized host, although this remains 
to be proven by controlled therapeutic studies.  
 
Although evidence of immediate, IgE-mediated hypersensitivity provides a rationale for allergen-specific 
immunotherapy (AIT), to date, there is relatively limited evidence of beneficial effects of AIT against M. 
pachydermatis in dogs. More data is required before this can be systematically recommended.   
 
Whilst some laboratories offer serological testing for IgG reactivity to M. pachydermatis, the clinical utility 
of this test is uncertain as there is no evidence of any diagnostic or therapeutic value.  
 
7. Predisposing factors 
Dog breeds identified to be at increased risk of Malassezia dermatitis include West Highland white terriers, 
English setters, shih tzus, basset hounds, American cocker spaniels, boxers, dachshunds, poodles and 
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Australian silky terriers. Devon rex and sphynx cat breeds are also predisposed. The presence of skin folds 
is a common risk factor for localised disease. Dogs with Malassezia dermatitis often have concurrent 
hypersensitivity disorders, cornification defects or endocrinopathies. Cats without a breed predilection most 
often have an underlying hypersensitivity disorder, or visceral neoplasia or other serious internal disease.  
 
8. Recommendations for skin sampling in dogs and cats 
Routine cytological sampling of skin sites in the veterinary clinic is best achieved by light microscopical 
examination (usually x 100 oil objective) of tape-strips or dry scrapes stained with modified Wright Giemsa 
stain (Diff-Quik [Harleco, NJ, USA] or generic equivalent). Cytology using swabs is normally best restricted 
to use in the ear canal. Factors such as important variations in anatomical site, breed, sampling method and 
host immune status commonly thwart the interpretation of the clinical significance of an observed population 
(“XX yeasts in YY fields”); trial therapy is routinely required to establish this.  
 
A single report indicates that the sharp end of a tooth pick is the preferred method for sampling the dorsal 
claw fold in dogs.  
 
Routine cultures provide primarily qualitative data on presence / absence of yeast, although ‘heavy’ growth 
on primary isolation plates likely indicates a high population. Modified Dixon’s agar is the preferred medium 
for the isolation and quantification for M. pachydermatis from canine skin, in view of the relatively rapid 
growth of colonies that are readily distinguished from cutaneous bacteria and its’ potential for supporting 
the growth of lipid-dependent isolates; incubation should be aerobic at 32-37oC for at least three days. 
Sabouraud’s dextrose agar (preferably supplemented with 1% Tween 80) is an alternative for dog samples 
if modified Dixon’s agar is unavailable, although occasional more-lipid dependent isolates will be overlooked 
with this medium; temperatures below 32oC should be avoided and use of 5-10% carbon dioxide should be 
considered.  
 
For cats, samples should be grown on modified Dixon’s agar at 32-34oC aerobically; cultures should be 
systematically extended to at least seven days in case of presence of slower growing Malassezia spp. 
Temperatures in excess of 34oC must be avoided because of the potential to inhibit the growth of thermo-
sensitive species such as M. globosa known to inhabit feline skin.  
 
Contact plates allow convenient, rapid and inexpensive quantitative culturing of M. pachydermatis from 
canine and feline skin; they are suitable for both diagnostic and research purposes. Optimally sized plates 
for cats and dogs (typically 18-27 mm diameter depending on site sampled) containing the preferred medium 
(modified Dixon’s agar) are not available commercially but are readily custom-made in mycology 
laboratories.  
 
Detergent scrub sampling is the ‘gold standard’ method for quantitative culture, although it is more suited 
to a research rather than diagnostic environment because it is suitable for only relatively flat skin on co-
operative animals and rapid sample processing is required. This is the optimal technique for mycological 
assessment in therapeutic product development.   
 
9. Diagnostic methods: molecular and mass spectrometry identification of yeasts in culture and 
skin 
Molecular techniques are pivotal in the accurate identification of many of the currently recognised Malassezia 
species with the usual exception of M. pachydermatis. In particular, sequencing of D1/D2 domain of the 
large subunit of the rRNA gene, ITS, IGS, CHS2 and ß-tubulin genes allows for accurate identification of 
species and recognition of genotypes that may have relevance for host-adaptation and virulence. Microbiome 
studies utilising next-generation sequencing have the potential to re-define the microbial ecology of 
mammalian skin. Multiplex PCR and MALDI-TOF MS hold promise for rapid and specific identification of 
Malassezia from skin and culture specimens, respectively.  
 
10. Histopathology 
A diagnosis of Malassezia dermatitis cannot be made by histopathology alone. Histopathological features in 
dogs often comprise hyperkeratosis or parakeratosis, irregular epidermal hyperplasia and spongiosis that 
extends to hair follicle infundibula, lymphocyte and granulocyte exocytosis, and a mixed, predominately 
lymphocytic, superficial perivascular or interstitial infiltrate with variable superficial dermal oedema. Yeast 
cells may or may not be observed in surface or infundibular stratum corneum (cytology or quantitative 
culture preferable for assessment of populations). In cats, histopathological features vary markedly 
according to the nature of the underlying disorder.  
 
11. Antifungal susceptibility testing and resistance 
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Testing for resistance is hampered by the unsuitability of the current CLSI and EUCAST reference methods, 
lack of an agreed modified protocol optimized for M. pachydermatis and absence of clinical breakpoints for 
either systemic or topical therapies. Despite these critical limitations, current data suggest that the vast 
majority of field isolates of M. pachydermatis are routinely susceptible to most relevant azoles (miconazole, 
clotrimazole, itraconazole, posaconazole and ketoconazole). However, the evidence that reduced susceptibility 
of M. pachydermatis to commonly used antifungal drugs may develop under both field and laboratory 
conditions highlights the need for surveillance and vigilance for the emergence of clinically relevant resistance. 
This is especially important in cases of canine atopic dermatitis, seborrhoeic dermatitis and chronic otitis 
externa where repeated treatments are commonly utilized. Improved and agreed reference methods designed 
to overcome the specific growth requirements of Malassezia spp. are therefore urgently required.   
 
12. Clinical presentations in dogs 
Erythema, usually with kerato-sebaceous scale (“greasy” material) and pruritus (minimal, mild, moderate 
or severe) dominates the clinical presentation, often favouring intertriginous zones. There may be concurrent 
hyperpigmentation, lichenification, malodour, traumatic alopecia and otitis externa. Some cases present 
with paronychia with claw fold erythema and swelling, waxy or crusty brown exudate, red-brown claw 
staining, or frenzied facial pruritus with varying, sometimes subtle, erythema of chin / perioral skin.  
  
13. Clinical presentations in cats 
Erythema, usually with kerato-sebaceous scale (“greasy” material) and pruritus (minimal, mild, moderate 
or severe) dominates the clinical presentation. There may be concurrent otitis externa and an observed 
breed predilection (Devon rex, sphynx). Malassezia dermatitis might feature in cats that present with a 
phenotype of allergic skin disease, idiopathic facial dermatitis (Persian / Himalayan), feline acne and serious 
internal medical disorders such as feline paraneoplastic alopecia and thymoma-associated exfoliative 
dermatitis.  
 
14. Diagnostic approach 
1. In dogs or cats with clinical presentations detailed in sections 12 or 13 above, establish whether Malassezia 
yeasts can be identified cytologically (or by quantitative culture using contact plates or detergent scrub; not 
routine swab culture) in lesional areas, or not. Counts may be high but not necessarily so.  
 
YES  Initiate trial therapy with appropriate topical and or systemic antifungal product. 
NO Sample more sites; use an alternative sampling method; reconsider diagnosis. 
 
2. Evaluate the clinical and mycological response to appropriate topical (3-4 weeks) and or systemic (2-4 
weeks) antifungal therapy 
 COMPLETE CLINICAL & MYCOLOGICAL RESPONSES - diagnose Malassezia dermatitis; consider 
possible underlying causes. 
 PARTIAL CLINICAL RESPONSE, COMPLETE MYCOLOGICAL RESPONSE - diagnose Malassezia 
dermatitis; investigate/treat ongoing underlying skin disease. 
 NO CLINICAL RESPONSE, COMPLETE MYCOLOGICAL RESPONSE - consider yeast presence incidental 
to other inflammatory disease. 
 PARTIAL CLINICAL & MYCOLOGICAL RESPONSES - suspect Malassezia dermatitis; review 
compliance; extend or intensify antifungal therapy. 
 NEITHER CLINICAL NOR MYCOLOGICAL RESPONSES - review compliance; consider abnormal drug 
absorption or metabolism, or drug resistance; change antifungal treatment and re-assess. 
 
15. Treatment of Malassezia dermatitis in dogs and cats. 
Amongst the various treatments utilised for Malassezia dermatitis in dogs, strong evidence is available only 
for the use of a 2% miconazole and 2% chlorhexidine shampoo, used twice weekly.  This may be considered 
to be the topical treatment of first choice, where available and locally approved, and when owners are able 
to apply the product effectively. Moderate evidence is available for a 3% chlorhexidine shampoo.     
 
For canine Malassezia dermatitis, there is moderate evidence for the oral use of ketoconazole at 5-10 mg/kg 
once or twice daily; and oral itraconazole at 5 mg/kg once daily or two consecutive days per week. Based 
on current limited evidence, the use of either of these two azoles is justified in canine cases and the final 
choice may depend on geographical differences in availability, regulatory status and cost. Rationale for 
itraconazole instead of ketoconazole includes the potential for intermittent dosing and a perceived tendency 
for itraconazole to be better-tolerated. However, definitive statistical evidence of superior safety and/or 
efficacy is lacking and cost-benefit analysis makes ketoconazole a more practical choice in some countries. 
Compounded formulations must be avoided due to unreliable bioavailability. Evidence for oral fluconazole is 
limited to a single study where it was used at 5-10 mg/kg once daily conjunction with cefalexin. Thus 
fluconazole requires further assessment, especially since in vitro MIC values are routinely the highest 
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amongst antifungal azoles utilised in veterinary medicine (section 10); this may correlate with intermittent 
anecdotal reports of treatment failures. Oral terbinafine warrants further evaluation due to partial beneficial 
effects in two trials and questionable stratum corneum concentrations in a pharmacokinetic study when 
given at the current dose of 30 mg/kg once daily.  
 
In cats, there is weak evidence only for the use of oral itraconazole at doses of 5-10 mg/kg daily; or 5 mg/kg 
on a seven days on / seven days off protocol. In view of this limited data, good safety profile and, in line 
with guidelines for feline dermatophytosis, itraconazole should be considered as the systemic azole of first 
choice in this species for Malassezia dermatitis. Topical chlorhexidine and azole products have not been 
evaluated although their use is intuitive as adjunctive or sole treatments where application is practicable 
and clinically appropriate, such as in localised infections. 
 
Treatment of chronic relapsing cases of Malassezia dermatitis in dogs and cats can be frustrating and may 
be limited by financial considerations. Identification and treatment of underlying causes is essential.  
 
16. Prevention of Malassezia-associated skin diseases in dogs and cats 
When predisposing factors cannot be controlled, regular topical treatment or pulse oral therapy are 
reportedly useful in minimising relapses. Topical treatments are preferred to systemic treatments for long-
term therapy because of a lower risk of toxicity. Topical prevention of Malassezia dermatitis in dogs might 
be achieved using 2% chlorhexidine / 2% miconazole or 3% chlorhexidine shampoo twice weekly, as has 
been previously recommended for treatment. Lesser frequencies may be useful in preventing relapse in 
some cases but there is currently no evidence to support this. Twice weekly application of three drops of 
topical hydrocortisone aceponate shows promise in the prevention of Malassezia otitis externa associated 
with allergic skin diseases. Pulsed therapy with itraconazole (5 mg/kg once daily, two days on / five days off 
for three weeks) has been shown to be efficacious in the treatment of Malassezia dermatitis (but not otitis 
externa) in dogs and thus should be effective as a preventative. There are only anecdotal reports of 
preventative efficacy of itraconazole for dermatitis at a once-weekly interval.   
 
17. Zoonotic potential 
Given the high prevalence of M. pachydermatis hand carriage by dog owners (as assessed by PCR) and the 
relative rarity of serious human infections by this organism, the overall risk for zoonosis is quite low, 
particularly among people who are immunocompetent. The need for good hand hygiene by individuals in 
contact with pet dogs and cats should be emphasised.  
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1 Introduction 
Scientists have been grappling with the complexity of the genus Malassezia and their associated diseases 
for decades. Their relevance to companion animal veterinary practitioners first became apparent in the 
context of canine otitis externa in the 1950’s, whereas their role in canine dermatitis was not established 
until more recently. Malassezia dermatitis is now recognised as a common skin disorder in canine practice, 
although it is encountered more occasionally in feline practice.  
 
The commissioning of this review by the World Association for Veterinary Dermatology (WAVD) is timely, 
given the marked advances in our understanding of these lipophilic yeasts as a consequence of significant 
scientific endeavour, not least the sequencing of the genomes of the majority of the recognised species. 
Molecular biological techniques have transformed the taxonomy of the genus from two species in 1989 to 
18 species at the time of publication, in the process explaining, at a stroke, many of the painstaking 
observations of phenotypic variation made by generations of mycologists.  
 
This is the second WAVD consensus document on superficial veterinary mycoses, following on from one for 
dermatophytosis.1 Whilst the headline title of our review is “diagnosis and treatment”, the complexity of 
Malassezia dermatitis in dogs and cats requires a wider-ranging review. Unlike the dermatophytes, which 
visit and potentially infect the non-immune host, Malassezia yeasts are commensal organisms, forming a 
reservoir of potential pathogens in the stratum corneum or mucosae, that may induce disease whenever the 
homeostatic balance of yeast virulence, on the one hand, and host immunity, on the other, is disrupted in 
favour of the yeast.  
 
Our review includes a full description of the genus, since six of the currently recognised species have been 
described on dogs and cats, and six more have been described in other species encountered by veterinary 
practitioners. The wide range of methods used to define and quantify Malassezia yeasts on skin is assessed; 
rarely does one investigator use the same method as the next, but the different methods often yield diverse 
and conflicting data; highlighting the strengths and weaknesses of each should promote careful method 
selection for future studies. A basic description of molecular methods is incorporated to aid the non-specialist 
reader in understanding how these techniques are currently applied to yeast identification and epidemiology, 
and how in future they may change our diagnostic approach to the case. A discussion of current concepts of 
yeast virulence and host immunity is a necessary prelude to a review of immunological methods in diagnosis 
and therapy, and in the context of the crucial consideration of the host pre-disposing factors, whose 
recognition and correction is key to the prevention of chronically-relapsing disease. 
 
As the title indicates, one of our principal objectives is to describe the range of clinical presentations in dogs 
and cats, along with a suggested approach to elucidating the role, if any, of Malassezia yeasts in each case. 
Our therapeutic recommendations are drawn from both a systematic review of published therapeutic studies 
(section 15.2).  Given the general paucity of high quality trials in this field, consensus views from the panel 
of authors have also been incorporated. Thus, our concluding summary of therapeutic options falls between 
the definitions of “Practice Guideline (Evidence-Based)” and “Practice Guideline (Consensus)”.2 Finally, in 
the spirit of a ‘one health’ approach, the zoonotic potential of these yeasts is reviewed.  
 
2 The genus Malassezia. General properties, phylogeny, genomic studies and species of 
relevance to veterinary medicine  
 
Malassezia yeasts form a well-defined and unique cluster of lipophilic fungi living almost exclusively on the 
skin and mucosal sites of warm-blooded vertebrates. The genus Malassezia (Baillon) is usually considered 
as a monophyletic taxon in the phylum Basidiomycota and subphylum Ustilaginomycotina, a highly 
diversified group of more than 1,500 species of plant pathogens.3 Molecular analysis has confirmed that the 
genus Malassezia is deeply rooted in the Ustilaginomycotina with a sister relationship to Ustilaginomycetes 
and Exobasidiomycetes.4 As a consequence, it was proposed that the genus should be assigned as its own 
class, Malasseziomycetes.4  During the last decade, the analysis of the genome of Malassezia yeasts has 
allowed a better understanding of how these fungi, whose ancestors were most probably plant or soil 
residents, manage to survive and develop in the cutaneous ecosystem and how they interact with other 
members of the cutaneous microbiota. In 2007 the first genome sequence of a Malassezia species (M. 
globosa) was published.5 A few years later, a similar analysis was performed for M. sympodialis6 and for M. 
pachydermatis.7 In 2015, a study reported the sequences, assemblage and annotations for the genomes of 
14 Malassezia species, including multiple strains of the most relevant species in medical dermatology (M. 
globosa, M. sympodialis, M. restricta and M. furfur).8  
 
The first remarkable feature of Malassezia genomes is their small size (~ 10 Mb), about half of the size of 
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other known basidiomycetous fungi, with some species having less than 4,000 predicted genes.5,8,9 This may 
reflect adaptation to the limited ecological niche of the yeasts. Gene family analyses indicate that Malassezia 
yeasts display unique characteristics comprising (i) a low carbohydrate-degrading capacity due to reduction 
of glycosyl hydrolase-encoding genes; (ii) a lipid dependence for growth due to lack of a fatty acid synthase 
gene and (iii) a concomitant expansion of lipid hydrolysing enzymes (such as secreted lipases, 
phospholipases and acid sphingomyelinases) that allow Malassezia yeasts to collect and use fatty acids from 
the skin or mucosal surfaces of their hosts. Analysis of the genomes also revealed the presence of unique 
genes with unknown function and which were probably acquired through horizontal gene transfer.8  
 
The sexual form of Malassezia yeasts is still unknown. However, a region corresponding to the mating type 
locus (MAT) has been identified for these yeasts;6 it has been suggested that if there is an extant sexual 
cycle for some of them that it is more likely to be bipolar or pseudo-bipolar, with two mating types, rather 
than tetrapolar as in many other basidiomycetous fungi.8,10 
 
On lipid-enriched media such as modified Dixon’s agar, Malassezia colonies are cream to yellowish, smooth 
or lightly wrinkled, glistening or dull, with the margin being either entire or lobate. Malassezia yeasts appear 
as small ovoid, ellipsoidal or cylindrical cells (1.5 to 6.0 µm by 3.5 to 8.0 µm). Reproduction is by budding 
on a broad base and from the same site at one pole (monopolar blastic development). Some Malassezia 
species are able to form filaments in cutaneous lesions but also in culture under specific conditions.11-13 
Malassezia yeasts have a thick cell wall (~ 0.12 µm) whose innermost layer shows a characteristic serrated 
structure.12,14-16  
 
The genus Malassezia (Baillon) was created in 1889 for a single species, M. furfur, observed in lesions of 
pityriasis versicolor, a common dermatological condition in humans.17 It took a long time to understand the 
lipid dependence of this kind of fungi and, as a consequence, to obtain and maintain Malassezia yeasts in 
culture.18 Conventional laboratory techniques could not be used and despite the description of numerous 
species, their accurate identification was not possible. In 1989, the genus Malassezia (Baillon 1889), also 
known under the generic name Pityrosporum proposed by Sabouraud in 1904, comprised only two taxa: M. 
furfur (syn. P. ovale, P. orbiculare), a lipid dependent species found on human skin and M. pachydermatis 
(syn. P. pachydermatis, P. canis), a species isolated from the skin of animals, especially dogs.  
 
In 1990, Simmons and Guého described the new species M. sympodialis which was characterized by a 
sympodial budding process.19 In 1996, Guého et al. had the opportunity to collect and examine many isolates 
from humans and animals.20 Conventional and modern spectrum techniques were employed to characterise 
these isolates, encompassing morphology, ultrastructure, physiology and molecular biology. The result was 
a complete revision of the genus Malassezia and the description of four new species (M. obtusa, M. globosa, 
M. slooffiae and M. restricta).20 Eleven more species were described subsequently by different groups and 
from varied hosts: M. dermatis,21 M. japonica22 and M. yamatoensis23 from humans in Japan; M. nana24 from 
cases of otitis externa in cats and cattle; M. caprae25 from goats; M. equina25 from horses; M. cuniculi26 from 
rabbits; M. arunalokei27 from humans in India; M. brasiliensis and M. psittaci28 from domesticated parrots 
in Brazil; and M. vespertilionis from bats in the USA29. Of these, to date, M. pachydermatis, M. furfur, M. 
sympodialis, M. globosa, M. slooffiae, M. nana, M. caprae, M. equina, M. cuniculi,  M. brasiliensis,  M. psittaci 
and M. verspertilionis have been isolated from animals and are therefore relevant in veterinary dermatology 
(Table 1).  
 
Malassezia species are lipid dependent due to an inability to synthesize long-chained (C14 or C16) fatty 
acids de novo.30 There are some differences in lipid dependence among the species and this variability has 
been used for the development of specific tests for the identification.31 Historically M. pachydermatis was 
regarded as being ‘lipophilic but not lipid-dependent’ because it was the only member of the genus to grow 
on Sabouraud’s dextrose agar. Recently, genome sequencing has confirmed that M. pachydermatis lacks a 
fatty acid synthase gene like the other members of the genus, but is uniquely able to utilise lipid fractions 
within the peptone component of Sabouraud’s dextrose agar for growth. These observations explain its 
failure to grow on lipid-free defined media and thus M. pachydermatis should now also be regarded as being 
‘lipid-dependent’.   
 
The phenotypic identification scheme for the routine identification of Malassezia currently includes 
microscopic features, ability to use lipid supplements (different Tweens and cremophor EL [polyethoxylated 
castor oil]), catalase and beta-glucosidase reactions, and temperature tolerance at 32°C, 37°C and 40°C 
(Table S1). Despite the undisputable value of this phenotypic identification scheme, ambiguous results are 
sometimes reported. Furthermore, the addition of recently identified species resulted in similar physiological 
patterns and thus in a doubtful identification (M. arunalokei and M. brasiliensis are closely related to M. 
restricta and M. furfur, respectively) (Table S1). For all these reasons, specific identification should be 
confirmed by DNA sequencing analysis. Various molecular loci had been proposed to identify Malassezia 
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species (section 9). The most frequently used loci are the D1/D2 domain of the 26S rRNA gene and the 
internal transcribed spacer (ITS) regions.32,33 Other genes such as chitin synthase-234 and ß-tubulin35 have 
been proposed for taxonomic purposes. Recently, mass spectrometry has also been utilised for the 
identification of Malassezia yeasts isolated from human patients in three French university hospitals.36 A 
MALDI-TOF database of main mass spectra has recently been developed to allow the rapid identification of 
14 Malassezia species.37 
 
2.1 Conclusions 
Malassezia yeasts are unique in several ways, including their strict dependence on lipids, their cellular 
ultrastructure and their dominance as eukaryotic residents on the skin of warm-blooded vertebrates. The 
taxonomy of the genus Malassezia is evolving. Eighteen species have been described so far but many other 
species are most probably present on the skin or mucosal sites of warm-blooded animals. Few phenotypic 
tests are available to differentiate Malassezia species and some of them may overlap. As a consequence, 
DNA sequencing (or other techniques like mass spectrometry) may be required for specific identification. 
 
3. Historical aspects of Malassezia yeasts as skin pathogens in dogs and cats 
 
3.1 Introduction: prehistory facilitating discovery 
Analysis of the history of scientific discovery highlights the influence of language and geography, the role of 
experts and opinion leaders in study centres or in the modern day ‘centres of excellence’, and wider cultural 
effects that may impede or enhance investigation and implementation of technological advances in the 
pursuit of scientific progress. The fascinating history of the genus Malassezia and its role in disease spans 
four centuries and three continents and extends from early microscopical observations through to present 
day genome sequencing. After a [final] flurry of controversy in the late 20th century, this body of evidence 
culminated in development of the disease model that veterinarians use today.     
 
3.2 The first reports of the yeast and disease 
3.2.1. Early reports 
1846 Karl Ferdinand Eichstedt was the first to observe hyphal elements and blastoconidia in scale from his 
patients and attributed these to cause a human skin disease he called “Pityriasis versicolor”.38  
 
1853 Charles Robin named Eichstedt’s fungus as Microsporon furfur, believing it to be a dermatophyte, and 
termed the associated skin disease “Tinea versicolor”.39 
 
1873 Sebastiano Rivolta, an Italian veterinarian, noticed a double-contour budding yeast in human 
“psoriatic” scales and gave them the name Cryptococcus psoriasis.40  
 
1874 Frenchman Louis Charles Malassez41 suggested that Microsporon furfur caused dandruff and correctly 
differentiated the yeast into genus of single cell fungi (“Saccharomyces”) rather than the dermatophyte 
complex. For this correction, his name was ultimately attached to the genus.42 
 
3.2.2. Attempts at classification without laboratory isolation  
1884 Bizzozero studied these microbes and described them to be part of normal human skin flora. He 
claimed there were two different species and named them Saccharomyces ovalis and S. sphaericus.43 
However, these were later shown to be a single species.44  
 
1889 Baillon created the genus Malassezia to accommodate M. furfur, in honour of Malassez, who was 
already acknowledged as having described the new species – at least in the French-speaking scientific 
community.17 However this particular yeast could not be grown and isolated in laboratory conditions because 
its lipid requirement in culture media were as yet unknown.  
 
1910 Raymond Sabouraud, a prominent medical mycologist, proposed the name Pityrosporum malassezi 
for this bottle shaped yeast thought to cause human dandruff.45 
 
1913 Alfred Kraus was able to culture P. malassezi in a medium containing lanolin.46 In a prime example of 
the effect of geography and historical events on scientific discovery, this German scientist’s work was largely 
overlooked with the onset of the First World War. 
 
3.2.3. Diseases associated with Malassezia 
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1925 Weidman reported bottle shaped yeast from the scale of the single horned Indian rhinoceros 
(Rhinoceros unicornis) with a generalised exfoliative dermatitis.47 In contrast to M. furfur this yeast 
cultivated readily on routine media without lipid supplementation. Weidman classified the yeast in the genus 
Pityrosporum, with the species name P. pachydermatis. The rhinoceros responded rapidly to topical therapy 
with 1% salicylic acid in lard.  
 
1928-9 McLeod and Dowling part-fulfilled Koch’s postulates by isolation of M. furfur from humans with 
seborrhoeic dermatitis in an oleic acid broth.48,49 They then inoculated lesion-free skin of a person with 
seborrhoeic dermatitis and a normal human with the broth isolate and reproduced seborrhoeic lesions in 
both, from which they re-isolated M. furfur. An incidental finding was an association between the dandruff, 
yeast and a concurrent coccoid bacterium that was carefully separated and subcultured. MacLeod and 
Dowling regarded these pyogenic micrococci as secondary invaders, even accepting it was constantly 
associated with seborrhoeic dermatitis.50 Interestingly, MacLeod and Dowling referred to three names of the 
yeast in their work: the ‘spore of Malassez’, ‘Pityrosporum of Sabouraud’ or the ‘flask bacillus of Unna’. Until 
now, no consensus had been reached as to whether these names covered a single organism, whether it was 
pathogenic and what disease was caused. This work was later confirmed by Moore and colleagues.51  
 
These publications, discussions and controversies were a prerequisite to unravelling the role of Malassezia 
spp. in skin diseases of the dog and cat.  
 
3.2.4. The controversy and ‘Dark Years’: 1940 to 1960 
1940-1960 are known as the ‘Dark Years’ and spanned a period of more controversy. The hard won 
progress in the field was forgotten as a consequence of the Second World War and the overwhelming effect 
of cortisone treatment becoming available in the late 1940s, to which human seborrhoeic dermatitis 
responded. The role of Malassezia yeasts in the disease was thus forgotten. 
 
1970 The systematics were rectified when Sloff in Lodder’s ‘The Yeasts, a taxonomic study’ assigned all 
Pityrosporum that grew on media without lipid enrichment as single species of P. pachydermatis.52, 53  
 
1984 The third edition of ‘The Yeasts, a Taxonomic Study’ (Yarrow and Ahearn) referred to the new genus 
Malassezia and confirmed that one species grew without lipid enrichment.54 This was later officially added 
into the taxonomical order.55 
 
1990 A new species, Malassezia sympodialis was described19 and by 1996 four new species were added to 
the genus.20 This species was later isolated from a cat by Bond et al. in 1996.56 
 
3.2.5 Modern approaches 
Currently there are 18 different species of Malassezia.35,57 The genus continues to expand and this is likely 
to continue as the classical ‘bottom-up’ microbiological approaches merge with organism-level genomics and 
community or ‘systems-level meta-genomics’.  
 
3.3 Malassezia yeasts in animals 
3.3.1. Canine ear and skin disease: the first reports (1951 to 1999) 
The discovery of Malassezia in animals occurred at a much later date than in humans. As mentioned, 
Weidman47 isolated yeasts from the skin of a rhinoceros in 1925, but research in domestic animals largely 
re-started 30 years later.  
  
3.3.2. Malassezia yeasts in the canine and feline ear  
1955 Gustafson was the first to notice a bottle shaped yeast in otitis externa of a dog; he correctly 
recognized them as Pityrosporum and created a new species P. canis.58 This was in error as he had misread 
Lodder’s description and failed to consider Weidman’s discovery of the yeast in rhinoceros skin, which grew 
without lipid enrichment. Gustafson was able to induce a spontaneously-resolving erythemato-ceruminous 
otitis externa in healthy dogs by the application of a suspension of ‘P. canis’ to the external ear canal.58 
 
1961 Fraser also isolated and studied strains of yeast from healthy and diseased dog ears and correctly 
ascribed all as P. pachydermatis. During the next two decades, a number of studies showed the connection 
between canine otitis externa and P. pachydermatis.59,60  
 
Page 12 of 68 
1976 Baxter also showed that, unlike previously thought, the frequency of isolation of P. pachydermatis 
was comparable in healthy ears and in cases of otitis externa in dogs’ and cats’ ears.61   
 
3.3.3. Canine skin disease 
1975 Dufait was the first to describe the skin disease, albeit in a local veterinary journal written in Dutch.62 
Also later, several non-English language studies were published,63-65 all describing canine Malassezia 
dermatitis; however, without a widespread English audience, many pruritic dogs suffered as a result of this 
disadvantage. 
 
1987 Mason66 spoke about three canine Malassezia dermatitis cases at the American Academy/College of 
Veterinary Dermatology meeting, creating objection and controversy, although another speaker from private 
speciality practice advised that he has seen a similar case. Similar discussions ensued at a lecture in 1992 
at the British Veterinary Dermatology Study Group spring meeting.67 One highlight of the debate was 
mention of Shuster’s publication that showed that dandruff was clearly associated with ‘Pityrosporum ovale’, 
elegantly dismissing the distorted view that effective dandruff treatments were cytostatic rather than 
antimycotic in action.68  
 
1988 Larsson et al.69 drew attention to Malassezia skin disease in the English language by describing the 
skin disease associated with P. pachydermatis. Mason and Evans confirmed and expanded on those earlier 
observations,70 although acceptance by the veterinary profession was not universal.  
 
1992 Pedersen published in Danish a case series of 10 dogs with Malassezia dermatitis.71 He described the 
cytology, mycology, histopathology and the results of antifungal treatment. The before and after clinical 
photographs left no doubt about the dramatic health and welfare benefits of the antifungal therapy in these 
cases.  
 
1996 Mason et al.72 followed up on knowledge of Malassezia associated dermatitis, staphylococcal pyoderma 
and demodicosis and integrated these into a unifying concept of skin commensals as opportunistic and 
complementary pathogens. By this time, the initial controversy that had dogged the profession regarding 
the significance of Malassezia yeasts as a cause for dermatitis in the canine had largely settled. 
 
Present day Currently, Malassezia pachydermatis is now well-recognized as a commensal yeast of dog’s 
skin and mucosa; overgrowth is commonly associated with otitis externa and dermatitis. Research continues 
in further characterising the relative pathogenicity of the different species and genotypes, and elucidating 
the factors that drive the conversion to pathogen (Figures 1a-c).  
 
3.3.4 Malassezia yeasts in cats: rare or common?  
The role of Malassezia spp. in feline skin disease beyond the ear canal had not aroused much interest until 
the research into canine and human Malassezia spp. carriage and associated dermatitis prompted some 
further work in the mid to late 1990’s.  
 
1976 Baxter was the first to report on M. pachydermatis in cat ears and as previously mentioned, found 
that Malassezia were also present in the ears of healthy animals.61 In 1990 Hajsig and Hajsig confirmed that 
M. pachydermatis is a normal part of cat skin microflora.73  
 
At the time Malassezia dermatitis was considered extremely rare or unknown in the cat. A causal relationship 
between the overgrowth of Malassezia in the cat and the development of seborrhoeic dermatitis was 
proposed in 1994.74 The two cats discussed had generalized exfoliative and greasy erythroderma which 
responded to antifungal therapy.  
 
1996 The isolation of M. globosa from skin of a healthy cheetah (Acinonix jubatus) represented the first 
report of lipid-dependent Malassezia spp from Felidae.20,75 Bond et al.56 isolated the first lipid dependent 
species (Malassezia sympodialis) from domestic cat skin. Subsequent studies by the same group and other 
groups in Spain and Japan led to reports on the isolation of M. globosa,76 M. furfur,77,78 M. nana24,79 and, 
more recently, M. slooffiae80-82 from domestic cats.  
 
2002 Mauldin et al. evaluated the presence of Malassezia yeasts in feline skin specimens submitted for 
histopathological examination from 1999 to 2000.83 Of the 15 cats with Malassezia, 11 presented with an 
acute onset of multifocal to generalized skin lesions and were euthanised or died within two months. In 
contrast to humans and dog, Malassezia overgrowth in the cat, in the absence of hypersensitivity disorder 
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or a breed predilection (Devon rex, sphynx) may indicate a poorer prognosis due to an association with life-
threatening systemic diseases.  
 
2005 Cafarchia et al.84 reported that both the frequency of isolation and population sizes of M. 
pachydermatis was increased in cats with otitis externa, when compared with healthy cats.84 
 
2007 Cats with seborrhoeic and allergic presentations were shown to have concurrent M. pachydermatis 
overgrowth that responded clinically to azole antifungal therapy, in parallel to the situation in dogs.80,85,86  
 
3.4 Conclusions 
The history of the association between Malassezia yeasts and its animal hosts has been long mired in 
controversy. Recent genomic studies have elucidated previously problematical aspects of taxonomy and 
indicated that genotypes and species of Malassezia are evolving as an adaptation to particular host ecological 
niches. Having been previously overlooked, canine Malassezia dermatitis has evolved from a controversial 
to a routine now diagnosis in small animal practice, with very significant welfare benefits for many animals.  
 
4 Ecology and Epidemiology 
 
4.1  Introduction 
Malassezia yeasts are common skin commensals in warm-blooded vertebrates. The loss of fatty acid 
synthetase genes (section 2), resulting in a requirement for a lipid source for growth, is likely one factor 
linking them to animal hosts. In one review,87 it was proposed that Malassezia yeasts are potential pathogens 
that operate in a pliable, physiological ‘transitional mantel zone’ that is influenced by both host skin and the 
animal’s external environment. Thus, yeast proliferation may be enhanced by either favourable 
environmental conditions (heat, humidity) and or changes in host susceptibility (section 7). 
 
Many culture-based studies have been carried out worldwide both in humans and in animals (especially in 
dogs) to better understand the ecology of Malassezia species on healthy skin and in cases with cutaneous 
lesions.33 Results are rarely comparable between studies because of the use of different sampling 
procedures, culture media and identification techniques. The influence of sampling methods and culture 
media on yeast counts are reviewed in section 8. The general conclusion is that M. pachydermatis remains 
by far the most important and prevalent species in dogs while the other lipid-dependent species are detected 
quite frequently in certain animal species (like cats) or body sites. Some of these lipid-dependent species 
seem to be host-specific (Table 1). In humans, three species (M. globosa, M. restricta and M. sympodialis) 
predominate.87 Interestingly human-related species may have a different geographical distribution; M. 
dermatis has been isolated in East Asia, M. arunalokei in India, whereas M. obtusa was mostly reported from 
Sweden, Canada, Bosnia and Herzegovina.27,33 
 
Malassezia yeasts have been isolated from almost all domestic animals, different wild animals in captivity 
and also from wildlife. An exhaustive list of potential animal hosts was reported in 2010.88 In addition, the 
presence of Malassezia-like organisms has been reported in a wide range of environmental habitats, from 
deep sea sediments, hydrothermal vents and arctic soils, to marine sponges, stony corals, eels, lobster 
larvae and nematodes.89-91  
 
In recent years methods based on next generation sequencing (NGS) have allowed a better characterization 
of the complex microbial communities occurring on the skin and made it possible to detect Malassezia species 
that would otherwise be missed using culture-based methods (section 4.4). 
 
4.2 Ecology of Malassezia yeasts in dogs 
Colonisation of canine skin probably occurs in the very first days of life; how this occurs is not understood 
but likely involves transfer from the bitch’s flora following removal of the amniotic membrane, licking and 
nursing in the same manner as staphylococci.92 In a study performed in 22 newborn Rottweiler puppies, 
Malassezia yeasts were recovered from around 40% of samples collected from the lips, nail beds and ears, 
at three, seven and 35 days of age.93 
 
Several investigators have explored Malassezia colonization in various anatomical regions of different breeds 
of adult healthy dogs; example studies that utilised culture methods are summarised in Table S2. There is 
some variability in the data, reflecting in part varied sampling methods; however, it can be seen that the 
sites most frequently colonised by M. pachydermatis in healthy pet dogs of various breeds are the peri-oral 
/ lip region (81% of 58 dogs sampled using contact plates) and interdigital skin (60-70% of 40 dogs sampled 
using contact plates) whereas the yeast is less-often detected in the skin of the axilla (12.5% of 40), groin 
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(23% of 91) and dorsum (4% of 73). The perianal skin and anal mucosa is a frequent (~55% of 73 dogs) 
carriage site whereas nasal and oral carriage is less frequent. Using cytological techniques, it was reported 
that the highest number of Malassezia were on the chin region, while inguinal and axillary zones presented 
the lowest number.94 Malassezia yeasts were identified by cytological methods in 10-31% of examined anal 
sacs in two studies of groups of healthy dogs (n=57),95 usually in low numbers.95,96 Malassezia yeasts were 
detected on the periocular skin of only three out of 56 (5%) clinically normal dogs.97 Basset hounds show a 
marked breed variation, with significantly increased frequencies and population sizes of M. pachydermatis 
in the nose, mouth, vulva and axilla.98 
 
Studies of oral carriage of Malassezia may have relevance as a source of transfer to the skin.99-101 Twice-
weekly application of a miconazole-chlorhexidine shampoo to seborrhoeic Basset hounds resulted in a 
significant reduction of M. pachydermatis populations in both the skin and mouth.99 Another study pointed 
out the possible transfer of Malassezia yeasts between the perioral area and pruritic skin lesions of the 
inguinal area as a consequence of frequent licking, and between undamaged interdigital regions as a result 
of persistent scratching.102 
 
Other than M. pachydermatis, lipid-dependent Malassezia yeasts are infrequently reported from dog skin. In 
initial reports, the identification of lipid-dependent yeasts was based only on morphological and physiological 
characteristics.84,103,104 In the absence of molecular techniques, there is scope to confuse lipid-dependent 
Malassezia spp. with atypical strains of M. pachydermatis that show inconsistent or stable lipid-
dependence.105,106 However, the presence of M. furfur was confirmed by molecular biology in dogs with 
cutaneous lesions107 or otitis108 in Brazil. In a survey in Slovakia, mycological cultures performed from dogs 
with cutaneous lesions (n=118) and dogs with otitis externa (n=328) yielded M. pachydermatis as the most 
frequently isolated species (121 isolates); however, four lipid-dependent isolates were identified as M. furfur 
and one as M. nana.109 
 
4.3 Ecology of Malassezia yeasts in cats  
The skin of Felidae is colonized by a diverse array of Malassezia spp yeasts. Whilst M. pachydermatis is most 
frequent, as in dogs, the lipid-dependent species isolated from domestic cats include M. sympodialis,56,76 M. 
globosa,76 M. furfur,77,78 M. nana,24,79 and M. slooffiae.80-82 The original reports of isolation of M. furfur are 
based on phenotypic rather than molecular methods. The isolation of M. globosa from the skin of a healthy 
cheetah (Acinonix jubatus) represented the first report of lipid-dependent Malassezia spp from cats.20,75 In 
2004, a study described M. nana, a novel species from aural discharges of a cat and cattle.24 Some lipid-
dependent strains similar to the M. sympodialis type strain and isolated from cats were studied using DNA 
sequence analysis and grouped together with M. nana.110 Malassezia nana seems to be the most common 
lipid-dependent species isolated from cats, particularly in the ear canal; similarities in the sequences of three 
loci of the rRNA gene,111 ß-tubulin gene and microsatellite profiles112 indicate that a particular M. nana 
genotype predominates in this host. Malassezia slooffiae is primarily but not exclusively associated with the 
feline claw fold.80 
 
Malassezia pachydermatis is less frequently isolated from cats than from dogs.73,75 Marked variations in 
Malassezia populations have been reported in the external ear canal of healthy cats. One study identified 
Malassezia yeasts in 43 out of 52 healthy cats sampled in the winter months in north eastern USA.113 By 
contast, another study failed to identify yeasts in 20 health cats sampled in France; notably in the latter 
study, the presence of cerumen was an exclusion criterion whereas cerumen was noted in many of the US 
cats, especially amongst those with a purely indoor lifestyle.114 Malassezia yeasts were detected in 20% (six 
of 30) ear canals of 15 cats with disease and in 43% (13 of 30) ear canals of 15 allergic cats.114 Devon rex 
cats and sphynx cats, but not Cornish rex cats, are prone to high carriage rates of Malassezia yeasts and a 
generalised seborrhoeic dermatitis that responds to oral itraconazole.80,86,115,116 Predisposing factors such as 
hypersensitivities and internal diseases that disrupt cornification are reviewed in section 7.  
 
4.4 Malassezia yeasts as components of the cutaneous microbiome 
The original cutaneous microbiome studies mainly focused on prokaryotic inhabitants; thereafter fungi 
received more attention in humans and also in dogs and cats.117,118 The first large-scale sequencing analysis 
which evaluated fungal diversity (“mycobiome”) on human skin clearly demonstrated that Malassezia yeasts 
are the most abundant fungal organisms on many human skin sites, as previously shown for the scalp.119-
121 In contrast to extensive bacterial diversity found at all human skin sites tested,122 the fungal diversity 
seems more site-dependent.121 Eleven Malassezia species were identified with M. restricta being 
predominant in the external auditory canal, retroauricular crease and glabella; while M. globosa was on the 
back, occiput and inguinal crease. The remaining species were detected across other body sites and with 
lower frequency.121 Reanalysis of these metagenomic datasets using a more complete set of Malassezia 
genomes demonstrated the presence of 12 species, with M. restricta and M. globosa by far the most 
abundant, distantly followed by M. sympodialis.8 The metagenomic analysis of skin samples from 40 
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asymptomatic individuals in Hong Kong revealed that 90% of the sequencing reads matched to M. 
restricta.123 Another study investigating 40 asymptomatic individuals in Japan indicated that Malassezia 
population differed by sex, body part and season.124 Another study reported a significant decrease in 
community diversity as an indication of skin disease in humans.125 
 
Only a very few studies examined the skin microbiota in dogs and cats.117,118,126-128 One study suggested 
that the main force driving the variability in microbiota composition was the individual, rather than the 
breed, hair coat or the skin site.126 Another study used NGS to define a much more diverse cutaneous 
mycobiota than that previously described with culture-based techniques in studies of healthy and allergic 
dogs.118 The cutaneous mycobiota appeared to be influenced by various factors including environmental 
exposure, cohabitation with other pets and skin health status. Surprising, Malassezia yeasts were not the 
most abundant fungal organisms on healthy canine skin. Sequences corresponding to filamentous 
contaminants from the environment (Alternaria, Cladosporium and Epicoccum spp.) were predominant. 
Furthermore, the same study was unable to detect any significant differences in the relative abundance of 
Malassezia yeasts between healthy and allergic dogs.118 In a similar metagenomic analysis performed in 
healthy and allergic cats, the most abundant fungal sequences were identified as filamentous contaminants 
from the environment (Cladosporium and Alternaria spp.) and not Malassezia yeasts, which were identified 
in 30% (35 of 108) and 21% (eight of 39) of healthy and allergic cat samples, but rarely accounted for more 
than 1% of the relative fungal abundance.117  
 
4.5 Conclusions 
Malassezia pachydermatis is a normal inhabitant of healthy canine skin and mucosae. Malassezia 
pachydermatis also predominates in the skin of the domestic cat, although other species are occasionally 
identified, particularly M. nana in the ear canal and M. slooffiae in the claw fold. Population sizes vary 
markedly between anatomical sites, and between different breeds. These commensal Malassezia populations 
provide a reservoir of yeasts that might proliferate and or induce an inflammatory response under the 
influence of various host predisposing factors.  
 
5. Pathogenesis: virulence attributes amongst Malassezia yeasts 
 
The interactions between Malassezia yeasts and the skin of their hosts, and the factors which influence 
transition from commensal to pathogen, are the subject of intensive scientific endeavour, especially 
pertaining to the common pathogens of humans (M. globosa, M. sympodialis, M. restricta and M. furfur).33,129 
Comparative genomic studies following the sequencing of 14 Malassezia species have significantly advanced 
opportunities for understanding of the adaption of the genus to its limited ecological niches (mainly skin), 
elucidation of virulence attributes necessary for colonisation and infection, and identification of novel 
interventional targets for therapy.8 In particular, the novel description of Agrobacterium tumifaciens-
mediated transformation systems that allows for the insertion of transfer DNA and targeted gene deletion in 
M. furfur, M. sympodialis and M. pachydermatis, and thus analysis of individual gene function, is certain to 
revolutionise our understanding of the biology of this genus.130-132 
 
The presence of a nutritionally absorptive fungus within the stratum corneum exposes the host to an array 
of chemicals, immunogens and allergens, comprising fungal cell wall-associated carbohydrates, proteins and 
lipids; secreted enzymes that generate both substrates for nutrition and an array of irritant metabolic by-
products. The cell wall of Malassezia spp. is unusual in thickness (90-150 nm14,133), morphology (inner 
spiralling / corrugation14,133,134) and composition (predominance of (1→6)-ß-D-glucan, trace of mannan135 
with unusual polysaccharide assembly136, chitin prominent in bud-scar137, lipid-rich wall and capsule6) 
(Figure 2). Interaction with other commensal microbes might also influence pathogenicity and expression of 
virulence factors.138-140 Thus, these commensal yeasts are likely highly regulated by continuous interactions 
with the host immune system (section 6)141 and these interactions ultimately determine whether the 
outcome is inflammation (i.e. fungal disease) or not.     
 
Adherence, the specific attachment of the microbe to host cells, is a key step in colonisation and infection 
of animals by commensal and pathogenic fungi.142 Adherence of M. pachydermatis to canine corneocytes 
has been reviewed in detail,143 and likely involves a small family of proteins that are covalently bound to cell 
wall carbohydrate and anchored to the plasma membrane.6 Malassezia cells adhering to keratinocytes have 
the potential to modulate the expression of an array of cytokines, chemokines and antimicrobial peptides, 
the outcome of which may be immune-stimulatory (as may occur in disease states, characterised by the 
development of cutaneous inflammation) or immune-suppressive (promoting commensal carriage)144 see 
review.143 A change in host immunity, altered skin microclimate or disruption in epidermal physiology 
associated with concurrent diseases (section 7) may predispose animals to clinical disease. Co-proliferation 
of staphylococci in the same lesions145 may exacerbate clinical signs and necessitates concurrent 
antibacterial therapy in some cases.146 The term ‘dysbiosis’ has been applied to similar microbial imbalances 
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within the cutaneous microbiome, albeit primarily in the context human and canine atopic dermatitis 
(cAD).118,147-149  
 
The Malassezia genus’ evolution to lipid-dependency is associated with a wide expansion of lipase and 
phospholipase genes, and loss of carbohydrate metabolism genes, although numbers of secreted proteins 
overall appear lower than those of related plant pathogens (section 2).150 Lipases, highly expressed in the 
skin of human patients with dandruff and seborrhoeic dermatitis, likely damage the epidermal barrier directly 
and by hydrolysis of triglycerides.151-153 Phospholipase activity in M. pachydermatis is stimulated by the 
endogenous opioid peptide ß endorphin present in the skin of dogs with dermatoses;154 activity was 
significantly higher amongst M. pachydermatis isolates derived from the dogs with otitis externa155 or skin 
lesions156,157 when compared with those obtained from the dogs with healthy external ears, or non-lesional 
skin, respectively. Similar observations have been made in pathogenic strains of M. restricta and M. globosa 
collected from lesions of seborrhoeic dermatitis in humans.158 Genotypic variants of M. pachydermatis with 
high phospholipase activity induced higher expression of pro-inflammatory genes from cultured human 
keratinocytes.159 Laboratory data indicated that phospholipase production might act in synergism with 
biofilm formation (layers of adhering yeasts embedded in variable quantities of extracellular matrix) to 
induce or exacerbate skin lesions in dogs.160 By contrast, a secreted aspartyl protease from M. globosa 
inhibited S. aureus biofilm proliferation and rapidly hydrolysed protein A, a major staphylococcal virulence 
factor.139 A correlation between biofilm formation and other virulence factors (hydrophobicity, adherence) 
was observed amongst 60% of 16 clinical isolates of M. furfur.161 The role of biofilm formation in potentially 
reducing susceptibility to antifungal drugs is discussed in section 10. Other enzymes from Malassezia yeasts 
such as acid sphingomyelinases and chitin deacetylases may also influence host-yeast interactions.162 
 
Malassezia yeasts from human skin have the ability to synthesise in vitro a large panel of indolic compounds 
(mainly malassezin, indolo[3,2-b] carbazole, pityriacitrin, pityrialactone and indirubin) when tryptophan is 
used as the single nitrogen source.33 These indoles act as potent ligands for the aryl hydrocarbon receptor 
(AhR), a nuclear receptor and transcriptional regulator with pleiotropic effects that include down-regulation 
of immune stimulation, modification of melanogenesis and epidermal cell function, and inhibition of 
antagonistic microbes.152,163 One study suggested that M. pachydermatis is able to induce activation of the 
AhR in human keratinocytes and to increase the expression of responsive genes and markers of epidermal 
differentiation.164 Since indole production was not detected in a study of 80 M. pachydermatis strains from 
canine otitis externa,165 AhR activation by M. pachydermatis might be associated with the release of 
compounds other than indolic metabolites. 
 
Malassezia cell wall carbohydrates have been long-recognised as IgE binding epitopes in humans with 
AD166,167 while other studies have highlighted their importance in fungal cell recognition by host phagocytic 
cells.168 C-type lectins are proteins that bind carbohydrates in a calcium-dependent (hence C) manner via 
highly-conserved carbohydrate-recognition domains.168 Langerin, a C-type lectin expressed by Langerhans 
cells that recognises mannose and beta-glucans, has a strong affinity for Malassezia and Candida spp. and 
is regarded as a major pattern recognition receptor for both commensal and pathogenic fungi.169,170 By 
contrast, Mincle, a C-type lectin expressed by activated phagocytes that binds glucosyl and mannosyl-
glycolipids from M. pachydermatis and M. sympodialis,171 selectively recognises Malassezia spp. but not 
other fungi.172 In co-operation with Dectin-2, another C-type lectin that recognises a distinct hydrophilic O 
mannobiose-rich protein, Mincle and Dectin-2 collaborate to enhance production of inflammatory cytokines 
such as TNF-α, MIP-2 and IL-10 from mouse activated phagocytes exposed to Malassezia furfur.171 C-type 
lectin-mediated innate immune mechanisms are discussed further in section 6.  
 
5.1 Conclusions  
There have been significant advances in the understanding of the mechanisms of interaction between 
Malassezia yeasts and their hosts. The outcome of Malassezia growth in the stratum corneum is dependent 
upon the metabolic activities of the yeasts (expression of cell wall and secreted virulence attributes) and the 
host’s innate and adaptive immune defensive responses; interactions with other skin commensals (especially 
staphylococci) may also play a role. All these processes should ideally result in a delicately balanced 
homeostatic relationship. Further studies are required to define fully the parameters that dictate transitions 
between commensalism and parasitism that may yield opportunities for novel preventative and therapeutic 
strategies.  
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6. Pathogenesis: immunological responses to Malassezia yeasts and their clinical relevance in 
diagnosis/therapy 
 
The presence of Malassezia organisms on the skin, both in normal and excessive numbers, is known to 
activate the skin immune system.173 There is now compelling evidence that Malassezia antigens can 
stimulate innate, antibody and cell mediated immune responses, as well as triggering hypersensitivity 
reactions.174 Although this immune response may offer a degree of protection in certain circumstances, it 
may also be harmful. In animals in which an overgrowth of organisms has occurred, or in individuals that 
are predisposed to allergic sensitization, the ensuing inflammatory response can lead to clinical signs such 
as dermatitis and pruritus. This section comprises a comparative review of human and dog studies; 
publications on immune reactivity to Malassezia species in cats appear to be lacking.  
  
6.1 Activation of keratinocytes 
The initial interplay between Malassezia organisms and the skin immune system is likely to take place in the 
epidermis.175 It has been demonstrated that application of M. pachydermatis suspensions on healthy dog 
skin can induce skin lesions similar to those observed in naturally occurring Malassezia dermatitis.176 This 
indicates that Malassezia cell surface markers or metabolic products derived from the yeast may be able to 
directly damage the skin or induce pathogenic effects by activating the skin immune system.173 In order for 
this to happen, antigens or allergens produced or expressed by Malassezia spp. would need to penetrate the 
stratum corneum in order to be recognised by Langerhans cells or keratinocytes. These would then act as 
antigen presenting cells able to sensitise and then activate the T lymphocyte population. An impaired barrier 
function, such as is seen in canine and human atopic dermatitis,177 is likely to facilitate transepidermal 
allergen penetration. Activation of keratinocytes by Malassezia is suggested by studies in humans which 
demonstrated that M. furfur could invade keratinocytes and resist phagolysosome fusion.178,179 Furthermore, 
M. sympodialis produces extracellular vesicles, enriched with the allergens Mala s 1 and s 7, that bind actively 
to and are internalised by human keratinocytes, potentially promoting sensitisation and maintenance of 
inflammation.180   
 
Keratinocytes recognise Malassezia antigens via Toll-like receptors,174 although they, along with other cells, 
can also be activated via the aryl hydrocarbon receptor following stimulation with Malassezia furfur-derived 
indole alkaloids such as malassezin, indirubin and indolo carbazole.175 These tryptophan-derived metabolites 
can trigger a variety of effects such as apoptosis of human melanocytes, but their precise role in cutaneous 
pathology remains to be determined. Once activated, keratinocytes can alter their cytokine expression, with 
up-regulation of the immunosuppressive cytokines IL-10 and TGF-β and down-regulation of the 
inflammatory cytokine IL-1α.181 Contradictory results have been reported for IL-6 and TNF-α with some 
studies demonstrating up-regulation and others showing down-regulation.181 Keratinocytes activated by 
Malassezia antigens also produce antimicrobial peptides but it is not known to what extent these are 
protective.182  
 
6.2 Activation of antigen presenting cells 
Activation of antigen presenting cells has also been demonstrated in vitro using human-derived immature 
monocyte-derived dendritic cells (MDDCs), which are analogous to Langerhans’ cells in the skin. These cells 
can take up whole M. furfur yeast cells and extracts, as well as recombinant M. furfur allergen 5 (Mal f 5)183 
Mala f 1184 and M. furfur mannan. The internalisation was shown to occur via binding to the mannose receptor 
and pinocytosis. Subsequently, the MDDCs underwent maturation, indicated by up-regulation of CD83 
expression and increase in expression of the co-stimulatory molecules CD80 and CD86. These mature 
dendritic cells are excellent antigen presenting cells and are capable of presenting peptides on MHC 
molecules to T cells.185 Dendritic cells have also been shown to be activated by interaction between 
Malassezia antigens and various members of the C type lectin class of receptors such as Mincle, Dectins 1 & 
2, and Langerin.175 This results in the production of pro-inflammatory cytokines such as IL-1, IL-6, IL-8 and 
TNF-α.175 A recombinant Mala f 1 gene fragment upregulated the production of IL-6, TNF-Alpha and IL-10, 
but not IL-12, from human leukaemia-derived dendritic cells.184 Interestingly, dendritic cells that have been 
stimulated by Malassezia antigens appear to be resistant to lysis by Natural Killer cells, a mechanism that 
likely favours survival of the cells in order to maintain antigen presentation.186  
 
6.3 T-lymphocyte mediated immune responses 
T cell-mediated immunity is important in the prevention and recovery from fungal infections and healthy 
human individuals demonstrate cell mediated immune responses throughout life.187 A deficiency in cell-
mediated responses could therefore predispose the host to overgrowth of Malassezia organisms. Cell-
mediated immune responses to Malassezia organisms have been investigated both in humans and dogs 
using assays such as leucocyte migration inhibition, peripheral blood mononuclear cell (PBMC) proliferation, 
immunohistochemistry, cytokine production, skin prick tests and atopy patch tests. Malassezia antigens and 
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extracts have been shown to stimulate proliferation of PBMCs in a dose dependent manner in both humans188 
and dogs.189,190 Furthermore, a reduction in PBMC responses was seen in seborrhoeic basset hound dogs 
compared to healthy basset hound dogs,189 although the role of this impaired response in the pathogenesis 
of Malassezia overgrowth in this breed is currently unknown.  
 
Despite the possible role of T lymphocytes in protective immunity, there is evidence that these cells are 
involved in sensitisation of humans and dogs that become allergic to the yeasts. Basset hound dogs with 
Malassezia dermatitis usually show delayed rather than immediate intradermal test reactivity to Malassezia 
antigens191 although contact sensitization, as demonstrated by patch test reactivity and characterised 
histologically by infiltration with CD3+ lymphocytes and neutrophils, more closely correlates with disease 
status in this breed.192 In both atopic humans and dogs, PBMC responses to Malassezia spp. are exaggerated. 
Malassezia antigens triggered significantly higher PBMC responses in atopic people compared to healthy 
individuals193-196 and this effect has also been demonstrated in atopic dogs.190 In P. orbiculare [syn. M. 
globosa] patch test-positive atopic dermatitis patients, an infiltration of CD4+ T cells is seen at the patch 
test site,197 and the expression of intercellular adhesion molecule (ICAM)-1 and human leucocyte antigen 
(HLA)-DR in the dermis of these patients was also up-regulated. Furthermore, in lesional atopic skin, the 
majority of the T cell clones that were reactive for P. orbiculare showed a Th2 or Th2/Th0 like cytokine 
profile195 and atopic human patients that are sensitised to Malassezia yeasts typically show increased 
synthesis of the Th2-related cytokines IL-4, IL-5, IL-10 and IL-13 by Pityrosporum [Malassezia]-stimulated 
PBMCs.196,198,199 Taken together, these findings provide compelling evidence that T lymphocytes play a 
pivotal role in the generation of hypersensitivity reactions to Malassezia species in genetically susceptible 
individuals. 
 
6.4 IgG, IgM and IgA responses to Malassezia yeasts 
As would be expected in a typical immune response against an infectious agent, antibodies directed against 
antigens from Malassezia yeasts are produced in healthy humans and dogs throughout life. IgM, IgG and 
IgA antibodies against Malassezia species are present in both young and elderly people, but the amount of 
IgG and IgM tends to tail off with age corresponding with declining numbers of commensal yeasts. 200-202 
The Malassezia-specific IgA concentration was found to be relatively low in all age groups. In dogs, serum 
titres of Malassezia-specific IgG and IgA in seborrhoeic basset hound dogs with high cutaneous populations 
of M. pachydermatis and affected dogs of various breeds significantly exceeded those of healthy basset 
hound dogs and healthy beagle dogs.189 Using Western immunoblotting to detect IgG responses in dogs to 
extracts of M. pachydermatis, four proteins of 219, 110, 71 and 42 kDa were shown to be recognised mainly 
by dogs with Malassezia dermatitis as compared to healthy dogs.203 
 
In humans with atopic dermatitis, the Malassezia-specific IgG concentration in adults is no different to that 
found in healthy individuals.194,197 However, in young atopic patients aged between 16 and 21 years, 
significantly elevated Malassezia-specific IgG concentrations are found.204,86 This probably reflects increased 
exposure to the organisms through atopic skin and a tendency for IgG to follow IgE production. Despite this, 
no correlation has been found between Malassezia-specific serum IgG concentration and atopy patch test 
responses to the yeast in patients with atopic dermatitis.197,63 It is therefore considered that determination 
of Malassezia-specific IgG concentrations has little value in the diagnosis of Malassezia sensitization in atopic 
human patients.178,197 However, concentrations of IgG4, a subtype that is induced in Th2 responses, are 
correlated with IgE concentrations in atopic patients with sensitivity to Malassezia sympodialis.205   
 
In atopic dogs with or without cytological evidence of M. pachydermatis overgrowth, there are significantly 
higher serum titres of Malassezia-specific IgG than those seen in healthy dogs.206 However, there was no 
significant difference between atopic dogs with or without Malassezia overgrowth. By comparing the IgG 
response to M. pachydermatis antigens using western immunoblotting, a protein of 25 kDa was identified in 
the majority of atopic dogs with Malassezia dermatitis, but only a few atopic dogs without Malassezia 
overgrowth and none of the normal dogs, suggesting that this protein may have some clinical relevance in 
the pathogenesis of Malassezia hypersensitivity.207  
 
In summary, it is clear that IgG responses to Malassezia yeasts are common in both healthy humans and 
dogs. This probably reflects exposure of the immune system to antigens produced by commensal organisms. 
However, enhanced IgG responses can be seen in dogs with Malassezia dermatitis and in humans and dogs 
with atopic dermatitis. The role of this IgG response in the pathogenesis of skin disease is currently unclear, 
both in humans and dogs. However, as overgrowth with Malassezia organisms does not appear to be a self-
resolving condition, it seems likely that these antibodies are not protective. Alternatively, IgG antibodies 
could activate the complement system, as has been demonstrated with Pityrosporum ovale [M. furfur] and 
P. orbiculare [M. globosa],208,209 and exacerbate the inflammatory response. A final possibility is that IgG 
responses to the yeast are merely an epiphenomenon and neither contribute to, nor inhibit, the ongoing 
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disease process. Further studies are therefore required to determine the precise role played by these 
antibodies in Malassezia-induced skin disease. 
 
6.5 IgE responses to Malassezia yeasts 
Increased concentrations of Malassezia-specific IgE are frequently present in atopic humans and dogs. 
Multiple studies have shown that IgE responses to Malassezia organisms are significantly higher in human 
patients with atopic dermatitis compared to those with other atopic diseases or healthy individuals.204,210-216 
In human patients with atopic dermatitis of the head and neck, the clinical severity of the condition is 
significantly correlated with the concentration of anti M. furfur IgE.217 Furthermore, IgE production by PBMCs 
stimulated with Malassezia extracts in vitro was significantly higher in radioallergosorbent test (RAST)+ 
atopic dermatitis patients compared with RAST- atopic dermatitis patients or healthy controls.198 This 
Malassezia-specific IgE has been found to correlate with the degree of response to Malassezia extracts in 
atopy patch tests at 48 h post-test in atopic dermatitis patients.197 
 
In humans, multiple proteins from Malassezia yeasts ranging in molecular size from 9-110 kDa have been 
characterised as major allergens in atopic dermatitis and a number have been sequenced and cloned, 
including Mal f 1-9 and Mal s 1-13.216,218-228 One particular allergen, Mala s 13, a thioredoxin enzyme, can 
cross-react with the human form of the enzyme, leading to the production of auto-reactive T cells that can 
sustain ongoing skin inflammation.229 A similar effect has been reported for Mala s 11, a manganese-
dependent superoxide dismutase enzyme that is found in both yeast and human cells.174  
 
In dogs, concentrations of IgE antibodies to M. pachydermatis are significantly higher in atopic dogs than in 
healthy dogs or non-atopic dogs with Malassezia overgrowth.206 However, dogs with recurrent Malassezia 
otitis had similar concentrations of allergen-specific IgE to those with healthy ears, suggesting that 
hypersensitivity is not always involved in such infections.230 Using Western immunoblotting to characterise 
individual antigen responses, proteins with molecular weights of 45, 52, 56 and 63 kDa from M. 
pachydermatis have been demonstrated to be major allergens in atopic dogs with Malassezia overgrowth.231 
 
These studies provide convincing evidence that proteins from Malassezia yeasts can act as allergens in dogs 
predisposed to the development of atopic dermatitis. 
 
6.6 Mast cell responses 
Studies have indicated that mast cells may be involved in innate immune responses against Malassezia spp. 
The interaction between Curdlan, a ß-glucan component of the cell wall of M. sympodialis, and C-type lectin 
pattern recognition receptors (such as Dectin-1) expressed on the surface of human cutaneous mast cells, 
induced degranulation and augmented IgE-mediated granule exocytosis.232 In other circumstances, fungal 
ligands may induce Dectin-1 mediated mast cell activation and production of chemokines and cytokines 
without degranulation.232   
 
In order to demonstrate full IgE-mediated hypersensitivity, it is necessary to document mast cell 
degranulation following allergen exposure. In humans, both intradermal tests (IDT) and skin prick tests 
(SPT) may show positive reactivity to Malassezia allergens in patients suffering from atopic diseases,213 
whereas these tests are usually negative in healthy controls. Stronger reactions are typically seen in patients 
with generalised atopic dermatitis,193,204,213 or those with lesions predominantly on the head and 
neck.219,222,233 The SPT results have also been found to correlate with levels of Malassezia-specific IgE in the 
serum204,234 and with results of basophil histamine release tests233 but not with the severity of atopic 
dermatitis.234  
 
Positive IDT results to Malassezia extracts have also been reported in atopic dogs.191 Immediate 
hypersensitivity responses to intradermal injections of M. pachydermatis extracts at concentrations which 
caused no reaction in healthy dogs have been observed in atopic dogs with Malassezia dermatitis, although 
they were also seen in some atopic dogs without Malassezia dermatitis.235 Nevertheless, the reactivity to 
the extracts in atopic dogs with cytological evidence of Malassezia overgrowth was significantly higher than 
that in atopic dogs without.191 Additionally, positive immediate hypersensitivity reactions to extracts from 
M. pachydermatis using Prausnitz-Küstner tests have been demonstrated.236 Clinically normal dogs received 
pooled sera from atopic dogs with Malassezia dermatitis that were IDT positive to Malassezia extracts and 
serum from an atopic dog with Malassezia dermatitis exhibiting high levels of anti-Malassezia IgE on an 
ELISA assay. Positive IDT responses were observed in the recipients following subsequent injection of the 
yeast extract, indicating that anti-Malassezia IgE antibodies are functional in Type I hypersensitivity 
reactions.236 As with intradermal testing to other allergens, there is reasonable agreement between the 
results of intradermal tests and IgE serology to yeast allergens, although it is possible to record a positive 
result in one test and a negative result in the other.237 The frequency of immediate hypersensitivity 
responses to M. pachydermatis extracts in non-atopic dogs with Malassezia dermatitis is low. One study 
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investigating IDT reactivity to M. pachydermatis in eight healthy basset hound dogs, 17 basset hound dogs 
with Malassezia dermatitis and 19 healthy beagle dogs, reported that only two affected basset hounds and 
one healthy beagle dog showed immediate hypersensitivity reactions.238 Taken together, these findings 
suggest that mast cell mediated hypersensitivity responses to M. pachydermatis allergens may be involved 
in the pathogenesis and contribute to the clinical signs in many cases of cAD. As a result of this Malassezia 
allergens are now typically included in standard intradermal allergen tests and IgE serology, although, to 
date, there is relatively limited evidence of beneficial effects of allergen-specific immunotherapy against M. 
pachydermatis in dogs.239  
 
6.7 Conclusions 
Based on the above studies, the likely sequence of events leading to immune responses to Malassezia yeasts 
can be summarized as follows: 
1. Malassezia species proliferating within the stratum corneum of dogs (and humans) produce numerous 
antigens and allergens. 
2. These antigens penetrate to the living epidermis and activate keratinocytes, resulting in the production 
of antimicrobial peptides and alterations in cytokine expression. 
3. Malassezia-derived antigens that permeate into and through the living epidermis are captured by 
epidermal Langerhans’ cells and/or dermal dendritic antigen-presenting cells. 
4. These cells then migrate to regional lymph nodes and present the antigen to a T lymphocyte via a 
major histocompatibility complex (MHC) class II molecule. 
5. In cooperation with different cytokines, T helper (Th) 0 precursor cells differentiate into Th1 cells and/or 
Th2 cells. A cytokine environment dominated by IL-12 would favour Th1 cell development, whereas 
IL-4 and IL-13 would stimulate the development of Th2 cells. 
6. T helper cells would activate B lymphocytes and stimulate them to differentiate into antibody–forming 
plasma cells. By secreting IL-2 and IFN-, Th1 cells would promote IgG production, whereas IL-4 and 
IL-13 from Th2 cells would promote immunoglobulin class switching to IgE. 
7. The production of Malassezia-specific IgG antibodies could potentially provide a degree of protective 
immunity against Malassezia organisms. Alternatively, these antibodies might activate the complement 
system causing epidermal damage and inflammation. 
8. The development of allergen-specific IgE antibodies could lead to sensitization of cutaneous mast cells. 
Subsequent exposure to Malassezia allergens could trigger the release of inflammatory mediators, 
resulting in a Type I hypersensitivity reaction. 
9. Circulating populations of Malassezia-specific sensitised T-cells might mediate delayed and contact 
hypersensitivity in selected patients.  
 
6.8 Implications for clinical diagnosis and therapy 
1. A range of immunological hyper-responsiveness can be present in dogs with Malassezia dermatitis 
(none, immediate, delayed, contact). Tests for immediate hypersensitivity (serology, intradermal) 
are relatively accessible (although not standardised) whereas delayed reactivity following 
intradermal testing is assessed infrequently and patch testing is technically challenging in the clinical 
environment.  
2. Serological and skin test reactivity is also seen in a proportion of unaffected dogs; thus 
immunological tests must be assessed in the context of clinical and cytological data; they should not 
be used as stand-alone ‘diagnostic’ tests.  
3. It is intuitive that evidence of immediate, IgE-mediated or cellular hypersensitivity might indicate 
the need for rigorous antifungal therapy to minimize allergen challenge in the sensitized host, 
although this remains to be proven by controlled therapeutic studies.  
4. Although evidence of immediate, IgE-mediated hypersensitivity provides a rationale for allergen-
specific immunotherapy (AIT), to date, there is relatively limited evidence of beneficial effects of AIT 
against M. pachydermatis in dogs. More data is required before this can be systematically 
recommended.   
5. Whilst some laboratories offer serological testing for IgG reactivity to M. pachydermatis, the clinical 
utility of this test is uncertain because there is no evidence of any diagnostic or therapeutic value.  
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7. Predisposing factors for development of Malassezia dermatitis 
Overgrowth of commensal Malassezia yeasts may occur due to alterations of the skin’s surface microclimate, 
leading to inflammatory skin disease.240 Primary diseases that cause increased moisture, altered surface 
lipids, and/or disruption of stratum corneum barrier function, or aberrant immune responses may encourage 
this secondary process of overgrowth.  
 
7.1 The role of gender, age and breed 
Gender and age do not appear to be consistently correlated with the presence of Malassezia dermatitis, but 
breed predilections in dogs have been described in several studies where cases were compared to the 
institutions’ general hospital67,241,242 or diagnostic laboratory243 populations. Breeds identified to be at 
increased risk by these studies include West Highland white terriers (WHWT), English setters, shih tzus, 
basset hounds, American cocker spaniels, boxers, dachshunds, poodles and Australian silky terriers. Breeds 
with conformations that favour skin folds are also prone to infections at intertriginous anatomical sites. The 
basset hound dog and WHWT in particular demonstrate clinically distinctive conditions characterized by 
generalized seborrhoea (basset hound)98,145 or generalized, severely pruritic dermatitis with marked 
lichenification and hyperpigmentation.244 It is noteworthy that all of these breeds are recognized to be at 
increased risk for developing ether atopic dermatitis or primary idiopathic seborrhoea. However, basset 
hounds in the UK that present with (an albeit relapsing) M. pachydermatis-associated seborrhoeic 
presentation typically respond dramatically to antimicrobial shampoo therapy with no residual clinical signs 
of atopic or seborrhoeic dermatitis.145   
 
Likewise, predisposed feline breeds have been recognized, although not through statistical analyses as 
compared to general hospital populations. Case-control studies in Devon rex cats and the sphynx breed, 
have demonstrated increased Malassezia counts as compared to domestic shorthaired cats.78,81,115,116 In 
these cases, Malassezia overgrowth is associated with the clinical finding of seborrhoeic skin; especially in 
the claw folds.78 
 
7.2 The role of cutaneous hypersensitivity disorders in the host 
Pruritic inflammatory diseases such as atopic dermatitis may create microclimate changes due to scratching 
(disruption of barrier function), licking (added moisture) or increased production of sebum.107 Despite the 
clinical observation that Malassezia overgrowth and atopic dermatitis commonly co-occur,107,245 studies have 
sometimes failed to demonstrate a clear statistical association between the two conditions.241,242 
Nevertheless it is generally accepted that M. pachydermatis may increase the inflammation associated with 
cAD directly by induction of inflammatory cytokines from epidermal cells and indirectly by acting as an 
allergen240,246 (section 6). Thus, a hypersensitivity response to M. pachydermatis might explain the 
discordance in the studies mentioned above since density of yeast on the skin’s surface cannot be used as 
the sole determinant of its pathogenic effect.246 However, in a study where cAD was the predominant 
diagnosis for a group of dogs with inflammatory skin lesions, there was a statistically significant correlation 
between higher CADESI-03 scores and increased colony forming units of M. pachydermatis isolated by 
quantitative culture.107 The range of epidermal barrier defects that might influence Malassezia-host 
interactions in cAD has been the subject of a detailed review.240 Malassezia spp. overgrowth has also been 
reported in series of cats with allergic skin disease.85,114 
 
7.3 The role of seborrhoeic dermatoses and aberrant cornification 
Primary and secondary seborrhoeic conditions also favour proliferation of Malassezia spp. Seborrhoeic 
dermatoses in dogs have been statistically associated with significantly higher M. pachydermatis skin surface 
counts as compared to healthy dogs.98,247 Similar associations have been described in cats with seborrhoeic 
disorders.80,115 Endocrinopathies such as hypothyroidism and hyperadrenocorticism may cause secondary 
seborrhoea in dogs; while no studies have demonstrated either disease to be an independent risk factor for 
Malassezia overgrowth, cases where an endocrinopathy and Malassezia dermatitis have occurred 
concurrently have been reported.241,242,248 In cats, no differences in Malassezia carriage were noted between 
healthy controls and cases with either hyperthyroidism or diabetes mellitus, using a contact plate technique 
for quantitative culture at several body sites; however, it should be noted that the cats with endocrinopathies 
in this study had no skin lesions at the time of sampling.82 
 
Malassezia overgrowth appears to be favoured by skin diseases with (assumedly) altered stratum corneum 
barrier function through aberrant cornification. Diseases of dogs characterized histopathologicaly by 
parakeratotic hyperkeratosis – such as zinc-responsive dermatosis and hepatocutaneous 
syndrome/superficial necrolytic dermatitis – have been anecdotally reported to promote yeast overgrowth 
(section 10).249 The presence of Malassezia overgrowth is associated with pruritus in American bulldogs with 
autosomal recessive congenital ichthyosis caused by a single base deletion in the gene NIPAL4.250-252 In 
cats, a histological study of 550 skin biopsy cases identified Malassezia overgrowth most commonly with 
thymoma-associated dermatosis (TAD) and paraneoplastic alopecia (PNA) associated with internal 
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neoplasia.83 In TAD, parakeratosis is a common histopathological feature, while PNA presents either with 
absence of a stratum corneum or some degree of parakeratosis.83 In one cat with TAD, resolution of 
Malassezia dermatitis was reported to occur after its thymoma was surgically excised.253 It is important to 
recognize that these diseases are not typically pruritic unless Malassezia overgrowth is present. Feline facial 
acne, thought to represent an idiopathic disorder of follicular keratinization, may also result in Malassezia 
overgrowth.254  
 
7.4. The role of climate 
The skin surface presents a range of natural micro-climates and several ecological niches with different 
moisture and nutrient levels may be recognised.255 The eyes, ears, nares, oral cavity, lip fold, prepuce, 
vagina and anus provide microenvironments that are moist with secretions and constitute unique ecological 
niches (section 4). The skin also presents gross topographical features that affect moisture and retain 
secretions such as the intertriginous zones and the interdigital spaces. It is from these areas that Malassezia 
overgrowth commonly develops. The external (macro-) environment may also play a role in predisposing 
dogs to Malassezia overgrowth. It is generally recognised that Malassezia dermatitis is more common in 
tropical climates and during warm, humid months in more temperate latitudes, in accordance with the 
concept that Malassezia yeasts inhabit a ‘transitional mantel zone’ that is influenced by both host skin and 
the animal’s external environment.87 Although not specifically studied in the dog, this factor is well-
documented in human medicine.33 
 
7.5. Factors of uncertain importance 
The role of immunosuppression as a risk factor for Malassezia overgrowth has been discussed anecdotally,70 
but no studies have examined the immunosuppressed state as a risk factor for animals with active yeast 
infection. In cats without skin disease, retroviral infection was associated with increased density of 
Malassezia spp. isolation from the hair coat as compared to non-infected cats.256  
 
Antibacterial therapy has not been reported to be an independent risk factor for development of Malassezia 
dermatitis in any published studies. However, a correlation between the onset of Malassezia dermatitis (or 
otitis) and the recent use of antibacterial drugs is sometimes observed by practitioners and could reflect a 
reduction in “competition” for micro-ecological resources as the bacterial population is reduced.242 However, 
the opposite has also been noted for individual dogs, where yeast counts dropped following treatment with 
cefalexin.146  
 
7.6. ‘Idiopathic’ cases. 
In a proportion of dogs and cats with Malassezia dermatitis, no concurrent disease or predisposing factors 
are identified.70,242 This is analogous to ‘idiopathic recurrent pyoderma’ and likely reflects incomplete 
understanding of, and an inability to investigate and define in detail any impairment of, the complex co-
ordinated innate and adaptive immune events that determine the outcome of skin colonisation by these 
yeasts (section 6). 
  
7.7 Conclusions 
Dog breeds identified to be at increased risk of Malassezia dermatitis include West Highland white terriers 
(WHWT), English setters, shih tzus, basset hounds, American cocker spaniels, boxers, dachshunds, poodles 
and Australian silky terriers. Devon rex and sphynx cats are also predisposed. The presence of skin folds is 
a common risk-factor for localised disease. Dogs with Malassezia dermatitis often have concurrent 
hypersensitivity disorders, cornification defects or endocrinopathies. Cats without a breed predilection most 
often have an underlying hypersensitivity disorder, visceral neoplasia or other serious internal disease.  
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8 Quantification of Malassezia populations on canine and feline skin by cytology and culture 
 
8.1 Background 
The assessment of the presence and number of Malassezia species is an important step in the 
characterisation of the cutaneous ecosystem of dogs and cats in both health and disease. Studies utilising 
traditional cytological and cultural methods have clearly demonstrated that Malassezia yeasts are normal 
inhabitants of healthy canine and feline skin and mucosae (section 4). 58,65,73,81,94,104,257-259 It is also clear 
that Malassezia overgrowth is a feature of a variety of clinical presentations in dogs 98,102,107,145,247,260 and 
cats.81,82,85,115,261 More recently developed molecular techniques have the advantage of being able to detect 
minority populations or organisms that cannot be cultivated using routine methods148, an issue that hindered 
progress with the lipid-dependent Malassezia spp. for decades.262 The molecular microbiome approach has 
led to a marked expansion of the diversity of bacterial genera shown to inhabit skin.148 The Malassezia genus 
has retained its status as the dominant fungal inhabitant of this ecological niche in humans 263, whereas dog 
and cat studies have shown a wider diversity of fungal genera, normally associated with an environmental 
source (section 4). The relatively low abundance of Malassezia spp.117,118 likely reflects the detection of 
transient environmental visitors rather than permanent residents.148  
 
Researchers and clinicians have developed a range of semi-quantitative and quantitative methods for 
enumeration of yeasts in skin, some of which have important applications in veterinary clinical practice for 
routine diagnosis, assessment of response to therapy, and in research and development of novel therapeutic 
agents and formulations. However, it is important to recognise that each have limitations that affect the 
final count;264 methods suitable for rapid assessment of Malassezia populations by veterinary practitioners 
‘on the clinic floor’ are not necessarily optimal for scientific research. The relative lack of sensitivity of 
histopathology for detecting Malassezia spp. in the stratum corneum is discussed in Section 10.  
 
8.2 Development and utility of skin sampling techniques for quantification of cutaneous 
Malassezia populations.  
Methods for microbiological assessment of skin populations have traditionally included impression (cytology 
using slides or tape; culture) and dispersal (primarily cup-scrub or swab-wash) methods.264 Impression 
culture methods tend to under-estimate microbial populations whereas dispersal methods yield values closer 
to the true population.265,266 Cytological examination without impression (scrapings, swab samples) are more 
recent developments.  
 
8.2.1. Impression cytology and related techniques  
Development. Early studies primarily utilised cytological techniques as Malassezia dermatitis emerged as an 
important inflammatory disease of dogs. These included scraping methods,70,267 direct impression with glass 
slides,69,241 or slide preparations prepared by rolling swabs previously rubbed on the lesional skin.70 One 
study elegantly described the utility of the direct application of vinyl adhesive tape in the assessment of 
cutaneous bacterial and fungal populations in human skin.268 A comparison of effectiveness of staining 
methods for detecting Malassezia cells in specimens from animals seems lacking, perhaps reflecting 
widespread satisfaction with a modified Wright-Giemsa stain (“Diff-Quik” [Harleco, NJ, USA] or generic 
equivalent) (Figure 3) that is likely to be available in the clinical area,67,269,270 although cotton-blue 
lactophenol69 and May-Grunwald Giemsa102 stains have also been used. 
 
 
Utility. Tape-stripping has gained wide acceptance in veterinary clinical practice as a rapid and versatile 
method for recovering stratum corneum cells and their attendant adherent microbes.271 It has also been 
used in a number of therapeutic studies,146,271 although these publications should be interpreted with due 
regard to the limitations of this method discussed below. Adhesive tape can be applied to deeply folded or 
recessed areas that are not readily accessible for direct slide application, often with minimal animal restraint. 
The adhesive properties aid removal of skin surface material especially in erythematous lesions with limited 
exudation. By counting yeast cells in a certain number of microscopical fields in the tape-strip sample, a 
known area of skin surface is examined.269 Different brands of tape vary in their ability to resist staining 
procedures without crinkling or becoming opaque and a ‘trial-and-error’ approach is needed to identify 
suitable products from amongst those available locally. Scotch tape (3M, St. Paul, MN, USA) and Sellotape™ 
Diamond Clear (Henkel Ltd. Hemel Hempsted, UK) often work well.  
 
8.2.2 Impression culture 
Culture of impression samples obtained using contact plates,272 adhesive tape273-275 or Denman brushes276 
for quantification of Malassezia spp. in skin was well described in human dermatology long before 
veterinarians became interested in this area, although contact plates have been used for the study of 
cutaneous bacteria in dogs.277-279 Squares of sterile carpet, popular for skin surface mycological sampling in 
France,280 have also been utilised for recovery of Malassezia spp. in dogs and cats.107,261,281 
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Development. The contact plate technique was shown to be a convenient, rapid and inexpensive method for 
the quantitative culture of M. pachydermatis from canine skin.260,282 Comparable yeast counts were obtained 
in four serial applications of contact plates containing modified Dixon’s agar to lesional canine skin. When 
incubated at 32oC, M. pachydermatis colony counts on contact plates after three and seven days of 
incubation were identical on both modified Dixon’s agar and Sabouraud’s dextrose agar (SDA), whereas day 
seven counts on both media were higher than day three counts when incubated at 26oC.283  
 
Utility for dogs.  The contact plate technique has been used to demonstrate significantly elevated groin 
populations of M. pachydermatis in atopic dogs.260 In healthy dogs, increased frequencies of isolation and 
population sizes of M. pachydermatis were found in the lip and interdigital skin when compared with truncal 
sites.259 Malassezia pachydermatis populations varied between anatomical sites in healthy basset hound 
dogs, with higher populations on the pinnae when compared with the perineal area.270 Contact plate counts 
of M. pachydermatis were reduced by both oral ketoconazole and oral terbinafine in healthy basset 
hounds,284 by climbazole shampoo in research beagle dogs,285 by chlorhexidine and climbazole wipes in a 
pilot study of five shar pei dogs.286  
 
Utility for cats.  Contact plate counts from the trunk were significantly higher in healthy Devon rex cats when 
compared to healthy domestic short-haired cats and Cornish rex cats; seborrhoeic Devon rex and sphynx 
cats had high yeast counts that exceeded those of the other groups.80,116 Contact plates were also used in 
two studies that assessed the beneficial therapeutic effects of oral itraconazole in cats with Malassezia 
dermatitis.86,287  
 
8.2.3. Dispersal methods – detergent (cup) scrub  
Development. A detergent scrub technique using wash fluid comprising 0.075 M phosphate-buffered saline, 
pH 7.9 and 0.1 per cent Triton X-100, first reported for studies of the human cutaneous bacterial flora,265 
and subsequently in studies of cattle266 and dogs,288-290 is considered the ‘gold standard’ method for 
quantitative culture.264,271 The method was also used to quantify Malassezia organisms on human skin.291,292 
In a series of development studies for quantifying M. pachydermatis on canine skin,293 counts of the yeast 
in suspension of pure cultures and in skin washings declined in contact with Triton X-100 and other 
detergents. Vortexing or manual or mechanical shaking of the samples yielded comparable counts. The 
technique was judged suitable for the quantitation of M. pachydermatis on canine skin provided samples 
were processed without delay and preferably within one hour of collection.  
 
Utility. Detergent scrub sampling supported a genetic predisposition to Malassezia overgrowth in basset 
hound dogs by demonstrating high populations (compared to healthy mixed-breed dogs) in the axillae of 
healthy hounds and even higher numbers in the axillae of seborrhoeic basset hound dogs.98 Detergent scrub 
counts were also used to evaluate and compare antimicrobial efficacy of shampoos in the treatment of 
seborrhoeic hounds.145    
 
8.2.4. Dispersal methods – swab wash 
Development. Microbial populations recovered using conventional swabs can be quantified by dispersing 
organisms from the swab tip using solutions containing detergents; counts can be achieved by plating serial 
dilutions onto relevant culture media. This method was used previously in the quantification of staphylococci 
from porcine,294 human295 and canine skin and/or mucosae.296 Malassezia pachydermatis counts did not vary 
significantly in each of four swabs applied serially to anus and external ear canal of healthy beagle dogs; 
dry swabs and moistened swabs had comparable efficiency at recovering the yeast.282 Yeast counts were 
comparable when swab tips held in wash fluid were shaken manually or vortexed for 30 seconds.  
 
Utility. Using the swab wash technique, the anus was the most frequently colonised site in healthy mixed 
breed and beagle dogs,259 whereas M. pachydermatis was more frequently isolated in higher populations at 
nasal and buccal sites in both healthy and seborrhoeic basset hounds.98 Swab-wash counts from the claw 
fold of sphynx cats and seborrhoeic Devon rex cats exceeded those of healthy domestic short haired, Cornish 
rex and Devon rex cats, whereas ear and anus populations were comparable.116  
 
8.3. Comparison of methods 
A number of investigators have evaluated the relative effectiveness of different sampling methods for 
Malassezia yeasts, primarily in dogs rather than cats. One early publication241 reported a subjective 
preference for direct impression using glass slides over use of cotton swabs, skin scraping and 
histopathology. Others found that both tape-strips and dry scrapes yielded high yeast counts from lesional 
skin whereas moistened swabs were much less efficient.269 Similarly, various authors have reported that 
swab cytology was inferior to superficial scraping,297 tape-stripping298 and conventional culture of swabs.84 
By contrast, Malassezia spp. yeasts and extracellular cocci were recovered in higher numbers from the dorsal 
claw fold (following skin eversion) by gentle scraping with the sharp point of a tooth pick, when compared 
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with tape-stripping and direct impression using glass slides,299 likely reflecting enhanced cell exfoliation from 
the hard cuticle of the claw surface in this specialised site.   
 
In a study of normal canine skin it was reported that the tape culture method was effective at recovering 
Malassezia but only low numbers of yeast cells were found in samples prepared by direct glass slide 
impression, skin scraping or cotton swab sampling.94 Malassezia pachydermatis was more frequently 
detected in a group of dogs with chronic dermatitis using a tape culture technique when compared with 
conventional swabbing.300 Potential growth interference from volatile antimicrobial components of the tape 
should be evaluated when this cultural method is utilised.273,301  
 
Yeast counts on diseased skin (18 sites in six dogs) measured by using detergent scrubs and a contact plate 
technique were significantly correlated whereas counts obtained by the tape-strip technique from adjacent 
skin did not correlate with either quantitative cultural method.293 Varied results were reported in other 
studies where tape-strip counts and contact plate counts have been compared.260,270 Contact plate counts 
typically yield M. pachydermatis population densities 100-fold lower than those derived by the dispersal 
detergent scrub technique259,293 and yeast cell densities measured by tape-strip.270,293 Thus, the contact 
plate technique may have low sensitivity for yeast detection when true populations are very low, but may 
prove more efficient when yeast are more abundant such as in clinical cases or in selected breeds with high 
populations in healthy skin.  
 
8.4 Culture media 
In quantitative investigations of the skin flora, the culture medium is known to have significant effects on 
the counts of Malassezia yeasts derived from human skin,272,292,302 prompting analogous canine studies. 
Amongst Malassezia spp., M. pachydermatis is the least fastidious and normally grows readily on routine 
media such as SDA,106 although M. pachydermatis variants with more-exacting lipid requirements have been 
isolated.105,303,304  
 
In early qualitative studies, the addition of 1% Tween 80 to a dextrose / yeast extract agar enhanced the 
isolation of M. pachydermatis.305 Tween 80 was not needed for the selective and differential isolation of M. 
pachydermatis in the presence of peptone,306 now recognised as the essential lipid source for growth of that 
species on SDA.18,106 Malassezia pachydermatis was isolated from swab wash samples in comparable 
numbers after three and seven days of incubation at 32oC on each of five media; SDA, SDA plus 1% Tween 
80, Ushijima’s medium A, modified Dixon’s agar and Leeming’s medium.283 After three days of incubation, 
the colonies were most distinctive on modified Dixon’s agar, forming buff-coloured domed colonies 1-1.3 
mm in diameter that were readily distinguished from other cutaneous microbes; on other media the colonies 
were low convex. Colony counts on contact plates were significantly greater after incubation for seven days 
on SDA and modified Dixon’s agar than after three days at 26oC, whereas three day and seven day counts 
were comparable at 32oC; this poor growth on SDA at 26oC was in accordance with previous53,307 and 
subsequent reports.281 Counts from swab-wash samples grown on SDA or modified Dixon’s agar for four or 
seven days were comparable at 32 and 37oC. When compared with aerobic culture, an atmosphere of 5-
10% carbon dioxide significantly increased the frequency of isolation and the colony counts on SDA but not 
modified Dixon’s agar in swab-wash samples incubated at 37oC for seven days.283 
 
One study compared Malassezia counts on SDA and modified Dixon’s agar from swabs and carpet squares 
at 27 and 37oC.281 The frequencies of isolation were significantly higher on modified Dixon’s agar at both 
temperatures after eight days of incubation; higher counts of larger colonies were cultivated on modified 
Dixon’s agar.  
 
To the best of the authors’ knowledge, there are no reports of comparative studies on quantification of 
Malassezia spp. from feline skin. Although M. pachydermatis predominates on both healthy cats and cats 
with dermatitis, lipid-dependent species such as M. sympodialis, 56,76 M. globosa,76 M. furfur,77 M. nana,79,116 
and M. slooffiae80,82,116 are occasionally encountered. Modified Dixon’s agar has proven suitable for the 
isolation of these species at 32oC over a seven day incubation period, whereas SDA does not support their 
growth.18 
 
8.5 Recommendations for culture  
Modified Dixon’s agar is the preferred medium for the isolation and quantification for M. pachydermatis from 
canine skin in view of the relatively rapid growth of distinctive colonies and its potential for supporting the 
growth of lipid-dependent isolates; incubation should be aerobic at 32-37oC for at least three days. SDA 
(preferably supplemented with 1% Tween 80) is an alternative for dogs if modified Dixon’s agar is 
unavailable, although occasional more-lipid dependent isolates will be overlooked with this medium; 
temperatures below 32oC should be avoided and use of 5-10% carbon dioxide should be considered.  
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In cats, samples should be grown on modified Dixon’s agar at 32-34oC aerobically; cultures should be 
systematically extended to at least seven days in case of presence of slower growing Malassezia spp. 
Temperatures in excess of 34oC must be avoided because of the potential to inhibit the growth of thermo-
sensitive species such as M. globosa known to inhabit feline skin.18  
 
8.6 Defining normal and abnormal populations of Malassezia spp. yeasts in the context of clinical 
reports  
Veterinary clinicians in speciality clinical practice are accustomed to systematically evaluating M. 
pachydermatis populations in inflammatory skin lesions in the majority of their canine and feline patients, 
most often with cytology; they will frequently record ‘elevated populations’ or ‘overgrowth’ in their clinical 
records. When these observations are subject to critical scientific review (such as when case series or reports 
are submitted to journals for publication) problems arise because reviewers and editors tend to prefer 
objective confirmation of such claims. This has resulted in definitions of abnormal populations in terms of 
“more than XX yeast cells in YY oil-immersion (x100) fields”.  
 
It is important to appreciate that these definitions are likely arbitrary unless previous studies established 
the likely values obtained with the identical sampling method in that particular anatomical site in that 
particular breed of dog or cat. Marked variations in populations between anatomical sites within the same 
dog are routinely described; for example, contact plates may yield confluent growth from the lip region of 
healthy dogs whereas counts are routinely much lower in the axilla and groin.259  
 
Breed variation is extreme in some circumstances, for example in basset hound dogs 98,308 and Devon rex 
and sphynx cats.80,115,116 It is important to note that high populations can be recovered from clinically normal 
skin; using the ‘gold standard’ detergent scrub samples, population sizes in healthy and seborrhoeic basset 
hound dogs were shown to overlap.98 ‘High’ counts need not necessarily be clinically relevant in each case 
where they are detected.98,259 By contrast, ‘normal’ or at least ‘lower’ populations may be sufficient to 
exacerbate cutaneous inflammation in patients with immediate or delayed hypersensitivity 
responses.246,309,310 Ultimately, a commensal existence or cutaneous disease caused by M. pachydermatis 
involves complex interactions between the yeast and its’ mammalian host that are not simply a result of 
achieving a particular number or density of yeast cells within the stratum corneum.  
 
8.7. Conclusions: recommendations for skin sampling in dogs and cats 
Routine cytological sampling of skin sites in the veterinary clinic is best achieved by light microscopical 
examination (50x or 100x oil objectives) of tape-strips or dry scrapes stained with modified Wright Giemsa 
stain (“Diff-Quik” or generic equivalents). Cytology using swabs is normally best restricted to use in the ear 
canal. Factors such as important variations in anatomical site, breed, sampling method and host immune 
status commonly thwart the interpretation of the clinical significance of an observed population (“XX yeasts 
in YY fields”); trial therapy is routinely required to establish this (sections 8.5 and 14.1-3).  
 
A single report indicates that the sharp end of a tooth pick is the preferred method for sampling the dorsal 
claw fold in dogs. 
 
Routine cultures provide primarily qualitative data on presence / absence of yeast, although ‘heavy’ growth 
on primary isolation plates likely indicates a high population.  
 
Contact plates allow convenient, rapid and inexpensive quantitative culturing of M. pachydermatis from 
canine and feline skin; they are suitable for both diagnostic and research purposes. Optimally sized plates 
for cats and dogs (typically 18-27 mm diameter depending on site sampled) containing the preferred medium 
(modified Dixon’s agar) are not available commercially but are readily custom-made in mycology laboratories 
that are accustomed to preparing their own media  
 
Detergent scrub sampling is the ‘gold standard’ method for quantitative culture, although it is more suited 
to a research rather than diagnostic environment because it is suitable for only relatively flat skin on co-
operative patients and rapid sample processing is required. This is the optimal technique for mycological 
assessment in therapeutic product development.  
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9. Diagnostic methods: molecular and mass spectrometry identification of yeasts in culture and 
skin  
The application of molecular biological techniques has underpinned the radical transformation of the 
taxonomy of the genus Malassezia over the last 30 years with an expansion from two to 18 recognised 
species (section 2).8,53 This section briefly reviews some of the more commonly reported molecular and mass 
spectrometry techniques that may be encountered in the veterinary literature on Malassezia species.  
 
9.1. Electrophoretic karyotyping 
Electrophoretic karyotyping involves the separation of intact chromosomal DNA according to its size on an 
agarose gel, generating specific banding patterns dependent upon the number and size of 
chromosomes.9,311 This technique differentiates between Malassezia species, but not between genotypes 
within each species.56,76,312 The ready availability of sequence-based methods has largely superceded this 
method in yeast identification.  
  
9.2 Ribosomal RNA gene sequencing 
Ribosomal RNA gene sequences have proven attractive targets for molecular fungal taxonomy on account 
of the presence of multiple copies in the genome and their tendency to have combinations of highly-
conserved sequences that may be recognised by pan-fungal PCR primers, separated by highly varied 
species-specific or genotype-specific domains. Amongst these, the D1/D2 domain of the 26S rRNA and the 
internal transcribed spacer (ITS) regions have been frequently used in the identification and phylogenetic 
studies of Malassezia species (Figure S1 and S2).26-28,32,304,313-315 Partial sequencing of the 26S rRNA of one 
hundred M. pachydermatis isolates identified seven sequence types, named sequevars (Ia-Ig); some of 
these variants seem to be host-specific for dog, ferrets and rhinoceros.303  
 
Marked sequence diversity of the intergenic spacer (IGS)(Figure S1 and S2) of M. pachydermatis isolated 
from dogs and cats enabled identification of three major groups (1, 2, 3) with 10 subtypes (1A, 1B, 1C, 
1D, 2A, 2B, 3A, 3B, 3C and 3D).316 In Japan, Korea and Taiwan, isolates of M. pachydermatis of subtype 3D 
were obtained more frequently from cAD skin lesions than from healthy canine skin.317 Moreover, subtype-
3D strains isolated from atopic dermatitis skin produced higher amounts of phospholipase A2 than did strains 
of other genotypes, supporting the hypothesis that the pathogenicity of this yeast is associated with the 
production of high levels of phospholipase A2.157 By contrast, lack of sequence diversity in the IGS region of 
M. nana isolates,111 and in the ß-tubulin gene and microsatellite profiles112 indicate that a particular M. nana 
genotype predominates in cats. 
 
9.3. Chitin synthase 2 and ß-tubulin genes 
Amplification of the chitin synthase 2 (CHS2) gene in seven Malassezia species yielded an ~620 bp fragment 
with 95% sequence homology between the species, although phylogenetic analyses indicated that each 
species was genetically distinct.34 Limited genetic variability in seen in the CHS2 gene amongst M. 
pachydermatis isolates from dogs in previous studies,318,319 although wider variation was observed in 
another study.57 Partial sequencing of the ß-tubulin gene in Malassezia provides a further opportunity for 
species and genotype differentiation.35,112,320 
 
9.4. Multilocus PCR approaches 
Genotypic approaches involving analyses of sequences obtained from multiple loci on the Malassezia 
genome, such as combined analyses of D1/D2, ITS, CHS2 and ß-tubulin sequences, has proven to be a 
powerful tool in the epidemiological assessment of the intraspecific variations and adaptation of these 
particular genotypes to specific hosts.35,57,304,321 
 
9.5. Random amplification of polymorphic DNA 
As the name suggests, random amplification of polymorphic DNA (RAPD) is a PCR-based method where 
short primers bind to random sites on the yeast genome to produce fragments that create specific banding 
patterns on electrophoresis. Whilst reproducibility is sometimes challenging, it is regarded as a useful 
epidemiological tool amongst Malassezia species.88 One study reported that RAPD analysis of M. 
pachydermatis indicated the existence of four different genotypes (genotype 1 to 4), with the genotype-1 
strains producing the highest amounts of biofilm and phospholipase activity.159 Moreover, the study also 
reported that the inflammatory response induced by M. pachydermatis strains in immortalized human 
keratinocytes (HaCat cells) was significantly higher in cells co-cultured with strain of genotypes 1 or 2.159 
Conversely, cells infected with strains of genotype 3 or 4 did not significantly induce expression of TLR-2 
and cytokines; overall these data further suggest a possible association between genotype and virulence 
factors expressed by M. pachydermatis strains. 
 
9.6. Next generation sequencing and the microbiome 
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Methods based on next generation sequencing (NGS) have allowed a better characterization of the complex 
microbial communities occurring on the skin and made it possible to detect Malassezia species that would 
otherwise be missed using culture based methods (section 4.4). 
 
9.7. Multiplex PCR 
A multiplex PCR method that utilized multiple hybridization probes for six Malassezia species, including M. 
pachydermatis, was reported to provide sensitive and rapid identification of Malassezia DNA in skin swab 
samples from both animals and humans.322  
 
9.7. MALDI-TOF mass spectrometry 
Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has emerged 
as a tool for identification of microbial cells or cell extracts.323 The method is rapid and sensitive, although 
identification of isolates is possible only if the spectral database contains fingerprints of the relevant species 
and strains. Mass spectrometry has also been utilised for the identification of Malassezia yeasts isolated from 
cases in three French university hospitals.36 A MALDI-TOF database of main mass spectra has been 
developed to allow the rapid identification of 14 Malassezia species (section 2).37 
 
9.8. Conclusions 
Molecular techniques are pivotal in the accurate identification of many of the currently recognised Malassezia 
species, with the usual exception of M. pachydermatis (which is readily distinguished from the other species 
by growth on Sabouraud’s dextrose agar). In particular, sequencing of D1/D2 domain of the large subunit 
of the rRNA gene, ITS, IGS, CHS2 and ß-tubulin genes or regions allows for accurate identification of species 
and recognition of genotypes that may have relevance for host-adaptation and virulence. Microbiome studies 
utilising next-generation sequencing have the potential to re-define the microbial ecology of mammalian 
skin. Multiplex PCR and MALDI-TOF MS hold promise for rapid and specific identification of Malassezia from 
skin and culture specimens, respectively.  
 
10 Histopathological features of canine and feline Malassezia dermatitis 
  
10.1 Background  
The histopathological features in skin biopsy specimens from lesions of Malassezia infection in dogs and cats 
commonly represent an amalgamation of features reflecting both the host response to the yeast as well as 
the concurrent, underlying disease. Preparation of the skin prior to biopsy and/or the ready loss of surface 
scale and yeasts during histological processing results in the number of yeasts observed by microscopy to 
be of questionable interpretative pathological significance. The issue of yeast number is compounded by the 
potential for hypersensitivity responses to Malassezia allergens to exaggerate the immunological reaction 
out of proportion to the population density of the yeast (section 6). Taken together, a diagnosis of Malassezia 
dermatitis cannot be made by histopathology alone; it is more realistic to limit expectations of histopathology 
to providing evidence of a consistent inflammatory process and/or indication of the nature of an underlying 
predisposing disorder. In routine cases, skin populations of the yeast are best assessed by cytology or 
quantitative culture (section 8). In some cases, histopathological approaches might be best employed after 
the yeast has been removed by appropriate therapy to enhance the characterisation of underlying disease.  
 
10.2 Experimental studies  
Cutaneous responses to the application of viable and killed Malassezia have been assessed both clinically 
and histologically in laboratory animals (guinea pigs, mice, rabbits) and humans, primarily with ‘lipid-
dependent’ Malassezia species isolated from humans (whose nomenclature pre-dates current revised 
taxonomy) applied under occlusion.324-327 Lesions generally comprised focal areas of scaling that most often 
resolved without treatment upon discontinuation of inoculation and were characterised histologically by yeast 
cells or hyphae in the stratum corneum, variable epidermal hyperplasia and superficial dermal inflammation 
with granulocytes and lymphocytes. Interestingly, Swiss white mice developed skin lesions whereas the 
nude (nu/nu) mouse, the hairless mice and nude rats did not.324 Inoculation of suspensions of M. 
pachydermatis into the middle ear and dermis of immunosuppressed mice led to transient infection that 
resolved within 21 days.328  
 
In laboratory beagle dogs application of M. pachydermatis was associated with epidermal hyperplasia, 
occasionally with parakeratosis, superficial perivascular dermal inflammation with primarily neutrophils and 
lymphocytes, and sometimes mast cells (but not eosinophils); features were more severe at sites that were 
occluded.329 Histological changes markedly reduced within seven days of withdrawal of yeast challenge.  
 
10.3 Canine Malassezia dermatitis 
Histopathologically, canine Malassezia dermatitis presents with variable but often marked hyperkeratosis 
and multifocal parakeratotic hyperkeratosis with the characteristic budding, bottle-shaped yeasts and often 
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cocci (if not lost during processing) over an irregular spongiotic epidermal hyperplasia that extends to the 
follicular infundibula; see reviews.83,330 Exocytosis of lymphocytes is a regular feature and neutrophilic or 
eosinophilic exocytosis may create epidermal microabscesses. Mast cell exocytosis is rare but a linear array 
of mast cells at the dermo-epidermal junction is not infrequent. Pigmentary incontinence is occasionally 
observed. The follicular ostia and infundibulae may be dilated with hyperkeratosis, occasional focal 
parakeratosis and yeast cells, with variable coccoid bacteria. The superficial dermis has variable oedema 
with interstitial and perivascular inflammation of lymphocytes (usually the dominant cell type), plasma cells, 
histiocytes, neutrophils and eosinophils.  
 
As mentioned above, it is important to recognise that yeast cells are not always observed; Malassezia cells 
were absent in 23 out of 86 cases in one study.243 The follicular ostia / infundibulae may be the best place 
to find yeast cells when numbers are low. Whilst visible in haematoxylin and eosin stained slides, periodic 
acid-Schiff or Grocott’s-Gomori methenamine silver stains accentuate the presence of the yeast.  
 
Authors in one study243 proposed standardized histological criteria for the ‘presumptive’ or final 
histopathological diagnosis of ‘Malassezia dermatitis’ comprising: 
1. pronounced irregular epidermal and infundibular hyperplasia;  
2. prominent epidermal and infundibular parakeratotic hyperkeratosis; 
3. diffuse epidermal and infundibular intercellular oedema (spongiosis);  
4. diffuse epidermal and infundibular lymphocytic exocytosis;  
5. superficial perivascular to interstitial dermatitis wherein lymphocytes are a prominent inflammatory 
cell type. 
6. presence of unipolar budding yeast in the surface and/or infundibular keratin. 
 
In the case of absence of budding yeasts, those authors243 regarded the histopathological diagnosis as 
‘presumptive’ provided the first five criteria were fulfilled. Unfortunately, similar features may be observed 
in skin biopsies from lesional skin in dogs with cAD,331 a disease whose signs may mimic or complicate those 
of canine Malassezia dermatitis.332 Features more supportive of Malassezia dermatitis include scalloping of 
epidermal and follicular margins, eosinophilic pustules and diffuse lymphocytic exocytosis, but none of these 
are pathognomonic.330  
 
10.4 Feline Malassezia dermatitis 
The histopathogical features associated with Malassezia dermatitis in cats are poorly defined although 
hyperkeratosis and irregular epidermal hyperplasia have been observed in association with abundant yeasts 
in the stratum corneum, analogous to canine features.261 The lack of description of the histopathology 
associated with these yeast in allergic and seborrheic cats that are otherwise healthy reflects infrequent 
biopsy sampling in cases more readily assessed by cytological techniques or culture.85 By contrast, more 
reports are available in cats with generalised infections that are often associated with visceral neoplasia or 
other serious internal diseases (Table S3).83  
 
10.5 Other conditions where Malassezia yeasts may be observed histologically 
Malassezia yeasts may proliferate opportunistically in response to skin disease and it is therefore not 
surprising that they may be observed in the stratum corneum in a variety of conditions. According to a 
standard textbook,330 Malassezia may feature in cases of bacterial intertrigo, feline hypersensitivity 
reactions, acrodermatitis of bull terrier dogs, atopic dermatitis, congenital follicular parakeratosis, facial 
dermatitis of Persian and Himalayan cats, familial paw pad hyperkeratosis, feline acne, feline paraneoplastic 
alopecia, feline thymoma-associated exfoliative dermatitis, female hyperoestrogenism, food allergy, 
hypothyroidism, ichthyosis, interdigital furunculosis, mucinosis, nasodigital hyperkeratosis, sarcoptic 
mange, seborrhoeic dermatitis, Sertoli cell tumour-associated skin disease, superficial necrolytic dermatitis 
and zinc-responsive dermatosis (Table S4).  
 
10.6. Conclusions 
A diagnosis of Malassezia dermatitis cannot be made by histopathology alone. Histopathological features in 
dogs often comprise hyperkeratosis or parakeratosis, irregular epidermal hyperplasia and spongiosis that 
extends to hair follicle infundibulae, lymphocyte and granulocyte exocytosis, and a mixed, predominately 
lymphocytic, superficial perivascular or interstitial infiltrate with variable superficial dermal oedema. Yeast 
cells may or may not be observed in surface or infundibular stratum corneum (cytology or quantitative 
culture are preferable for assessment of populations). In cats, histopathological features vary markedly 
according to the nature of the underlying disorder.  
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11 Antifungal susceptibility testing and resistance 
 
11.1 Introduction 
Antifungal chemotherapy is widely used in the treatment of a range of clinical presentations in both humans 
and animals that are attributable to cutaneous Malassezia. Previous reports have highlighted varied in vitro 
drug susceptibility results amongst the different species and within genotypes of selected species.333,334 The 
need for surveillance of antimicrobial resistance (AMR) in general has increased in parallel with the 
emergence of AMR as a significant threat in both human medicine and animal health. This section reviews 
literature relevant to Malassezia spp. and identifies areas for future development.  
 
11.2 Methods 
The susceptibility test is critical for the selection of treatment strategy and the control of drug-resistant 
pathogens and in circumstances where the organism’s susceptibility cannot be reliably predicted by its’ 
identity. In 2008, the Clinical and Laboratory Standards Institute published the most recent document (CLSI 
M27-A3) in its’ series of reference standards for susceptibility testing of yeasts.335 However, these focused 
on invasive human pathogens such as Candida and Cryptococcus spp. but M. pachydermatis does not exhibit 
sufficient growth in the standard defined (and lipid-free) RPMI 1640 medium to permit use of the reference 
method for this species. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
analogous reference susceptibility test for pathogenic yeasts and moulds336 also specified use of an RPMI-
1640 based culture medium that is unsuitable for Malassezia spp. Establishment of reference susceptibility 
tests for M. pachydermatis may ultimately depend on work by organisations such as the International Society 
for Human and Medical Mycology (ISHAM) working groups or the Veterinary Committee on Antimicrobial 
Susceptibility Testing (VetCAST), a subcommittee of EUCAST. In the absence of standard methods 
appropriate for M. pachydermatis the CLSI M27-A2 and A3 protocols have been adapted by various 
modifications of the process (Table S5).333,334,337-340 Technical specifics were usefully reviewed in detail, 
including a discussion of the effects of medium and conditions of incubation, lipid supplementation, inoculum 
preparation, end-point determination and quality control aspects.341  
 
Modified Etest protocols and conventional disc diffusion (CLSI M44-A) have also been used to determine the 
in vitro susceptibility of M. pachydermatis (Table S5 and S6); tests of this type are more suited to routine 
diagnostic use than broth dilution methods.333,337,342 The CLSI-recommended medium (Mueller-Hinton agar 
supplemented with glucose and methylene blue) optimally supports the growth of M. pachydermatis provided 
the inoculum is incubated with a lipid source (Tween 40 or 80); agar diffusion using clotrimazole and 
miconazole discs on this agar yielded values that correlated with MIC determined by broth dilution.343 Etest, 
a commercially-available manual in vitro diagnostic method that utilizes a plastic strip with a predefined 
gradient of antimicrobial agent, was used to establish MIC values for ketoconazole and itraconazole that 
reportedly correlated well with those obtained using a broth dilution method.334 One limitation is that strips 
are not available for all antifungal agents used in dogs and cats.   
  
11.3 Breakpoints: clinical versus epidemiological  
A breakpoint is defined by EUCAST as “specific values of parameters such as minimum inhibitory 
concentrations (MICs) or inhibition zone diameters on the basis of which microbes can be assigned to the 
clinical categories ‘susceptible (sensitive)’, ‘intermediate’ and ‘resistant’”.336 There is scope for confusion 
around use of the term breakpoint. “Clinical breakpoints” indicate to the clinician the likelihood of therapeutic 
success when using a particular antimicrobial against an infectious agent. “Epidemiological cut-off values” 
(ECOFFs) (syn. epidemiological or microbiological breakpoints) represent the highest acceptable MIC value 
of the wild-type microbial populations with no acquired phenotypically detectable resistance mechanism344; 
it is important to note that this might not be clinically relevant if the MIC is still below that achievable with 
the drug at any given site of infection. Unfortunately, interpretive breakpoints for antifungal susceptibility 
testing of Malassezia species are not yet available; thus, any classification of isolates into susceptible, 
intermediate and resistant categories remains speculative. This may be especially challenging in the context 
of topical therapy where high local concentrations are often achieved.345 Review of existing literature on M. 
pachydermatis susceptibility testing suggest that, in some cases, previous use of the term “resistant” would 
be best regarded as an ECOFF rather than a clinical breakpoint334,346 although further studies are required 
to confirm this hypothesis.   
  
11.4 Antifungal drug susceptibility testing in Malassezia species  
11.4.1. Azole antifungal drugs 
Imidazoles such as clotrimazole, climbazole and miconazole are used topically (most commonly in otic 
products, creams or shampoos) although ketoconazole and its triazole derivative itraconazole are widely 
available for oral use in dogs and cats. Posaconazole, a triazole structurally similar to itraconazole, is used 
orally or intravenously for the treatment of invasive mycoses in immunocompromised humans,347 and 
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topically in dogs with Malassezia otitis. Clinical efficacy with these products corresponds to multiple, 
systematic reports of low MICs in vitro with drugs of this class,333,334,338,348 with the exception of fluconazole 
(see below).  
 
11.4.2. Terbinafine  
Terbinafine is a synthetic allylamine derivative that inhibits fungal ergosterol biosynthesis at the point of 
squalene epoxidation. Terbinafine was first shown to have activity in vitro against Malassezia spp. more than 
30 years ago,349 although in the same study terbinafine activity was 20-800 times greater amongst a range 
of dermatophytes. Subsequent to conflicting reports of efficacy using topical versus oral dosing in human 
pityriasis versicolor, in vitro studies showed lower MICs in isolates of M. sympodialis that correlated with 
efficacy of oral dosing; higher MICs in M. globosa, M. restricta, M. slooffiae and M. furfur sensu stricto350 
were associated with better responses to the higher concentrations achieved by topical therapy.351 These 
species-related differential susceptibilities were confirmed in a subsequent study, with M. sympodialis and 
M. pachydermatis showing greatest susceptibility amongst examples of relative tolerance amongst other 
Malassezia species.352  
 
Further studies in collections of field isolates of M. pachydermatis have routinely indicated susceptibility at 
concentrations similar to those obtained with azole antifungal drugs. In a study of 24 M. pachydermatis 
isolates (urea broth dilution), mean MIC values of terbinafine were favourably comparable to those of 
itraconazole, although ranges or MIC90 values were not reported.353 Similar activity was found 
(supplemented RPMI 1640 medium) with a single M. pachydermatis strain.333 In a study of 62 canine derived 
M. pachydermatis strains (Christensen’s urea broth, supplemented RPMI 1640), terbinafine was superior 
(based on MIC90) to fluconazole by six two-fold dilutions but inferior to ketoconazole and itraconazole by 
three and five dilutions respectively.338 These values were barely exceeded in a pharmacokinetic study of 
skin concentrations achieved after oral dosing at 30 mg/kg sid.354 In another study (Sabouraud’s broth with 
1% Tween 80) of 216 colonies of M. pachydermatis obtained from 28 dogs with otitis (n=25) or dermatitis 
(n=3), terbinafine was superior (based on MIC90) to fluconazole by five two-fold dilutions but inferior to 
ketoconazole and itraconazole by one and four two-fold dilutions respectively.340 A similar relationship 
between terbinafine and ketoconazole susceptibility was noted in a study (supplemented Sabouraud’s broth) 
of 51 M. pachydermatis strains from canine ears.355  
 
11.4.3. Nystatin  
The polyene cyclic macrolides, amphotericin B and nystatin, were amongst the earliest broad-spectrum 
antifungals introduced for clinical use.356 The potential toxicity of amphotericin B generally limits its use in 
veterinary medicine to serious progressive or disseminated systemic mycoses, whereas nystatin is active 
when applied topically.357 Its mode of action is via altered cell membrane permeability mediated by 
preferential binding to ergosterol. These drugs were regarded as reference agents in early studies of M. 
pachydermatis susceptibility to azoles because of well-established activity against the genus,358 although 
polyene-resistant strains have been induced in vitro by exposure to mutagen (N-methyl-N'-nitrosoguanidine) 
or UV irradiation.359  
 
Wild type M. pachydermatis strains appear routinely susceptible to nystatin, although higher MICs (MIC90 
increased by a single two-fold dilution) have been reported amongst isolates obtained from dogs with skin 
disease when compared to isolates from healthy dogs (reportedly RPMI1640).348 In a study of 51 strains 
from canine ears (supplemented Sabouraud’s broth), nystatin was inferior to ketoconazole and terbinafine 
by seven and four two-fold dilutions, respectively.355  
 
11.4.4. Chlorhexidine 
Previous studies of the activity of chlorhexidine against M. pachydermatis have primarily utilized dilutions of 
commercial products rather than conventional reference methods with the drug in its’ pure form.360-363 
Although most of these studies have evaluated very small numbers of isolates, a common theme is that M. 
pachydermatis is typically susceptible to dilutions of chlorhexidine products, in accordance with reports of 
clinical efficacy. To the best of the authors’ knowledge, reduced susceptibility to chlorhexidine in vitro has 
not been reported. 
 
11.4.5. Gentamicin and other aminoglycosides 
Gentamicin is an aminoglycoside antibiotic with activity against many aerobic Gram-positive and negative 
bacteria, commonly formulated in polypharmacy otic products for dogs. Whilst gentamicin has been used as 
an inhibitor of bacterial growth in cultures of M. pachydermatis from ear swabs from laboratory dogs with 
high bacterial colonisation283, a subsequent report indicated that 20 of 20 isolates were susceptible to high 
concentrations in vitro.364 Further studies (Sabourauds agar, Christensen’s urea broth with Tween 40 & 80) 
have shown a wide variation in effect, with MICs’ of gentamicin ranging from 1.0 to >150 ug/mL.365,366 
Netilmicin, tobramycin and framycetin also have variable but often high activity against M. pachydermatis.367 
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These studies indicate that gentamicin might not be an optimal drug, for suppression of bacterial growth, in 
culture media intended for the primary isolation of M. pachydermatis and that further studies are warranted. 
The extent of any clinical benefit of anti-Malassezia activity from gentamicin in otic formulations used in 
canine otitis externa requires further assessment.  
 
11.4.6. Other drugs 
A small number of publications report activity in vitro of other agents against Malassezia spp. These include 
plant-derived substances such as Blad-containing oligomer (an antifungal agent approved for agricultural 
use);368,369 beta-thujaplicin,355 a honey-based gel,370 kanuka and manuka371 and other plant-derived 
essential oils;372 agents primarily used in the topical treatment of human dandruff or seborrhoeic dermatitis 
(selenium sulphide, zinc pyrithione, ciclopiroxolamine,373 rilopirox374) and povidone–iodine.375 The 
calcineurin inhibitors (tacrolimus and pimecrolimus) have activity in vitro against human-associated 
Malassezia yeasts.376 The clinical relevance of these observations for canine and feline infections requires 
further assessment.  
 
11.4.7. Combinations of antifungal drugs 
Combining antifungal drugs might potentiate their efficacy, reduce the selection pressure for resistance, 
reduce side effects if lower doses can be used and achieve clinical efficacy when monotherapy is 
ineffective.377,283 In a study of 30 M. pachydermatis isolates from canine otitis externa, primarily indifferent 
and often divergent interactions were observed between azoles and nystatin, terbinafine and caspofungin, 
although 55% (16 of 30) of isolates showed a synergistic interaction between caspofungin and itraconazole 
or fluconazole.377 By contrast, amphotericin B antagonised the activity of itraconazole, but not fluconazole 
or posaconazole, in approximately 55% of 30 otic isolates of M. pachydermatis in a broth micro-dilution 
checkerboard system.378 An additive interaction between fluconazole and calcineurin inhibitors against M. 
globosa and M. restricta is mediated by the immunophilin gene FKBP12.131 
 
11.5 Reports of reduced susceptibility to antifungal drugs amongst Malassezia yeasts 
 
11.5.1. Selecting for resistance in the laboratory 
In a study of 10 selected isolatess of M. pachydermatis from canine ears (supplemented Sabouraud’s broth), 
terbinafine MIC50 increased by three two-fold dilutions when sub-cultured 30 times in Sabouraud’s broth 
containing terbinafine at concentrations close to the original MIC.355 Similarly, nystatin MIC50 increased by 
a single two-fold dilution when sub-cultured in the same way and ketoconazole MIC50 increased by four two-
fold dilutions. From work in Malassezia and other pathogens, reduced susceptibility to azoles may be caused 
by reduced affinity due to alterations in the drug target enzyme,379 by increased expression of the target 
gene (ERG11) encoding this enzyme, or by increased efflux by overexpression of genes encoding membrane 
transport proteins of the ABC transporter (CDR1/CDR2) or the major facilitator (MDR1) superfamilies.356 
Induction of high fluconazole MICs in 30 strains of M. pachydermatis by prolonged exposure was associated 
with elevated MICs to other azoles, suggesting that the molecular basis for these effects may in some cases 
confer cross-resistance to this drug class.380 Further studies are needed to define the molecular genetics of 
the reduced susceptibility to azoles, terbinafine and nystatin induced in M. pachydermatis by laboratory 
exposure at sub-inhibitory drug concentrations and any implications for long-term drug use in clinical 
practice. 
  
11.5.2. Studies of field isolates 
Malassezia spp are reportedly not susceptible to echinocandins and griseofulvin.381 The inherently lower 
antifungal potency of the triazole, fluconazole, is largely compensated by its excellent pharmacokinetic 
properties for deep-seated infections of humans.356 Amongst collections of M. pachydermatis, fluconazole 
consistently returns significantly higher MICs when compared with other clinically relevant imidazoles and 
triazoles,339,340,373,382 leading to questionable predicted clinical utility of this agent in dogs and cats, pending 
development of clinical breakpoints and further clinical studies.383  
 
In 2010 a study reported the first itraconazole and ketoconazole “resistant” isolate of M. pachydermatis, 
originating from canine seborrhoeic dermatitis.337 Subsequently, it was reported that Italian clinical isolates 
of M. pachydermatis from canine skin lesions had low susceptibility to azoles compared with those from 
normal canine skin.338 Another study expressed concern about the phenomenon in the worldwide context, 
given that secondary infections with M. pachydermatis in cAD are frequently treated using azole-containing 
shampoos.342 These authors investigated azole (itraconazole and ketoconazole) susceptibility amongst M. 
pachydermatis isolates from cAD cases in East Asia over a two year period (2010 and 2011) by Etest using 
Sabouraud’s dextrose agar supplemented with 0.5% Tween 40.342 MICs amongst isolates from cAD isolates 
were significantly higher than the isolates from healthy dogs, in parallel to studies of isolates from healthy 
and seborrhoeic dogs from the same region.384 Treatment failure in a dog with idiopathic M. pachydermatis 
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dermatitis that had received years of previously successful treatment using a combination of pulse oral 
itraconazole and topical therapy was associated with elevated MICs to azoles in vitro.385 
 
Similar observations were made in studies of M. pachydermatis isolates from dogs with chronic otitis externa. 
One study reported that most M. pachydermatis isolates from canine otitis externa cases were inhibited by 
clotrimazole, miconazole and thiabendazole, at concentrations of 2-8 (clotrimazole), 1-4 (miconazole) or 16-
32 (thiabendazole) μg/mL.345 MICs were higher in M. pachydermatis isolates from chronic otitis dogs that had 
been previously treated with various topical ear products containing miconazole and clotrimazole.360 Another 
study examined in vitro antifungal susceptibility of M. pachydermatis isolated from cases of canine otitis 
clinically nonresponsive to either topical miconazole or clotrimazole and recognized MICs above the limit of 
detection for miconazole and clotrimazole in some isolates.386 Another study reported that high MICs of 
itraconazole and ketoconazole in a strain of M. pachydermatis from canine dermatitis were associated with 
missense mutations in the ERG11 gene.387 An additive effect of itraconazole in combination with tacrolimus387 
likely reflected calcineurin-inhibitor binding to the immunophilin FKBP12, as shown previously for additive 
interactions with fluconazole in M. furfur and M. sympodialis.131 
 
It is important to note that products formulated for treatment of canine otitis routinely contain concentrations 
of the drug that are at least 650 times the MIC of the wild-type target pathogen. Therefore, antifungal 
concentrations in topical products typically exceed, by several orders of magnitude, the highest MIC values 
reported to date for azole-resistant strains.  
 
11.5.3. Biofilms 
Biofilms, wherein groups of adherent microbial cells become embedded in an extracellular polymeric matrix, 
may protect the microbe from the host immune system and reduce susceptibility to antimicrobial drugs.160 
One study evaluated the in vitro antifungal susceptibility of M. pachydermatis strains, in both their planktonic 
and sessile (biofilm production) forms to fluconazole, posaconazole, voriconazole, miconazole, ketoconazole, 
itraconazole and terbinafine; MIC values were increased by 3-6 two fold dilutions in the sessile form.382 
Another study reported an increase in itraconazole and ketoconazole MICs by nine two-fold dilutions (<0.03 
to >16 ug/mL) following biofilm formation in M. pachydermatis, either alone or when co-cultured with 
Candida parapsilosis.388 A further study also reported that effective concentrations (EC50) of ketoconazole 
and itraconazole MICs increased by 18-169 and 13-124 times respectively against M. pachydermatis in 
biofilms when compared to planktonic forms.389 Another study reported reduced susceptibility of M. 
pachydermatis biofilms to azoles, terbinafine and amphotericin B.390 The significance of these important 
observations for therapy in clinical practice remains to be determined.  
 
11.5.  Conclusions: clinical context and implications for practice 
Testing for resistance is hampered by the unsuitability of the current CLSI and EUCAST reference methods, 
lack of an agreed modified protocol optimized for M. pachydermatis and absence of clinical breakpoints for 
either systemic or topical therapies. Despite these critical limitations, current data suggest that the vast 
majority of field isolates of M. pachydermatis are routinely susceptible to most relevant azoles (miconazole, 
clotrimazole, itraconazole, posaconazole and ketoconazole). However, the evidence that reduced 
susceptibility of M. pachydermatis to commonly used antifungal drugs may develop under both field and 
laboratory conditions highlights the need for surveillance and vigilance for the emergence of clinically-
relevant resistance. This is especially important in cases of cAD, seborrhoeic dermatitis and chronic otitis 
externa where repeated treatments are commonly utilized. Improved and agreed reference methods 
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12 Clinical presentations in dogs 
 
12.1 Signalment 
Malassezia dermatitis can potentially occur in dogs of any age, sex or breed, but signalment related 
predispositions have been reported. Malassezia dermatitis is often first diagnosed in dogs between one and 
three years of age,391 as might be expected in a disease that is frequently secondary to atopic dermatitis or 
due to genetic predisposition. Important breed predispositions are discussed in section 7.1.67,241,242 There is 
no sex predisposition.  
 
12.2 Historical features 
Malassezia dermatitis typically presents as a pruritic dermatosis or otitis and it is a major differential 
diagnosis in any dog with those presenting signs. The severity of pruritus can vary, ranging from mild to 
very severe. In one report, the onset of clinical signs coincided with the summer or humid months and then 
persisted into winter,392 but this apparent seasonality has not been verified to be independent of an 
underlying seasonal allergy. The pruritus can manifest as face rubbing, head shaking, ear scratching, paw 
licking/chewing, anal scooting or generalized scratching, depending on the location of infection.392 A pruritic 
facial hyperaesthesia is occasionally seen in association with Malassezia cheilitis.67,392 
 
12.3 Skin lesions and distribution 
The skin lesions in dogs with Malassezia dermatitis can be localised or generalised.70,267,392-394 Regional 
dermatitis commonly occurs on the muzzle, lips, ventral neck, axillae, ventral abdomen, medial hindlimbs, 
interdigital skin, perineum and in the external ear canal and intertriginous areas. Malassezia paronychia may 
occur in some cases. Some clinicians have observed anecdotally that a localized area of Malassezia 
overgrowth can occur following persistent licking. On examination, skin lesions are characterised by diffuse 
erythema and variable amounts of kerato-sebaceous scale that can be brown (Figure 4), yellow or grey in 
colour.330,392 The skin and hair coat may become greasy and self-induced alopecia can occur due to the 
pruritus. When paronychia is involved, there is reddish-brown staining of the claws (Figure 5) or hair, with 
inflammation of the surrounding soft tissue. Chronic cases can have marked lichenification. 
Hyperpigmentation can also occur with chronicity, depending on the breed; for example, West Highland 
white terriers typically develop this change with chronic disease (Figure 6), whereas basset hounds typically 
do not.145 Dogs with generalised lesions often have an offensive, rancid odour.  
 
Although the occurrence of severe generalized alopecia, lichenification and hyperpigmentation in the West 
Highland white terrier breed has been reported previously as a form of genetic epidermal dysplasia,244 many 
veterinary clinicians believe this condition is a severe manifestation of allergic skin disease and concurrent 
Malassezia dermatitis. Similarly, historical reports of an idiopathic seborrhoea non-responsive to etretinate 
in West Highland white terriers and basset hounds may have reflected untreated Malassezia dermatitis.395   
 
Malassezia overgrowth in the ears typically results in a pruritic, erythematous, ceruminous otitis externa 
which results in the accumulation of a brownish discharge. As on the skin surface, the medial aspect of the 
pinna can become lichenified in chronic cases. 
 
It is uncertain how the range of immunological hyper-responsiveness to M. pachydermatis present in dogs 
with Malassezia dermatitis (none, immediate, delayed, contact; section 6) influences the spectrum of lesion 
type and severity in affected dogs.  
 
12.4 Concurrent diseases 
Many dogs with Malassezia dermatitis have concurrent dermatoses, especially hypersensitivity disorders, 
ectoparasitic infestation, bacterial pyoderma, endocrinopathies or cornification defects (section 7). This can 
complicate the diagnosis, or lead to misdiagnoses, due to overlapping of clinical signs. These diagnostic 
challenges are compounded by lack of direct correlation between yeast population density and clinical signs 
(section 8.5). However, it is also important to remember that in some cases, especially in predisposed 
breeds, there is no identifiable underlying cause and the dog’s skin disease may respond completely to 
antifungal therapy.  
 
12.5 Conclusions: clinical presentations in dogs 
Erythema, usually with kerato-sebaceous scale, and pruritus (minimal, mild, moderate or severe) dominates 
the clinical presentation, often favouring intertriginous zones. There may be concurrent hyperpigmentation, 
lichenification, malodour, traumatic alopecia and otitis externa. Some cases present with paronychia with 
claw fold erythema and swelling, waxy or crusty brown exudate, red-brown claw staining, or frenzied facial 
pruritus with varying, sometimes subtle, cheilitis or erythema of chin / perioral skin.  
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13. Clinical presentations in cats 
 
13.1 Malassezia dermatitis and paronychia 
The clinical presentation of feline Malassezia dermatitis varies markedly depending on the underlying disease 
(section 7). Malassezia yeasts (chiefly M. pachydermatis) have been associated with a greasy seborrhoeic 
dermatitis in cats with or without concurrent paronychia.396 Predisposing diseases include poorly defined 
genetic factors (in Devon Rex and sphynx cats),80,86,115,116 feline atopic dermatitis (which may present with 
concurrent bacterial pyoderma),85,261,287,397 adverse food reaction,261,287 flea bite hypersensitivity,287 
although some recurrent cases are idiopathic despite diagnostic investigation.74,287 There is conflicting 
evidence for diabetes mellitus as a predisposing cause.82,287,398 Feline immunodeficiency virus-positive cats 
have been shown to carry more Malassezia organisms compared with normal cats but this was not associated 
with any clinical signs.399  
 
Affected Devon Rex and sphynx cats typically show mild to marked greasy seborrhoea with alopecia (in 
Devon Rex) and hyperpigmentation or reddish-brown surface discolouration and variable erythema affecting 
the axillae, groin, ventral neck and predominantly ventral interdigital regions. This is commonly accompanied 
by a greasy, tightly adherent brown exudate on the claws and/or in the claw folds of multiple digits. Pruritus 
is not typically a feature.78,115  
 
Less common presentations reported in Devon Rex cats include generalized seborrhoea sicca, a greasy 
seborrhoea affecting the ventral neck and head and pruritus.115 In sphynx cats in particular, there may be 
some elevated Malassezia carriage (compared with normal cats) which may result in greasiness without 
overt inflammation or seborrhoea.85,116 
 
Allergic cats show more variability in their presentation and may present with concurrent bacterial 
pyoderma.85,397 Dermatitis may be localised or generalised with pruritus, alopecia, erythema and greasy 
exudate. The most commonly affected body regions include the face, chin, neck, limbs, abdomen and ear 
canals (see below). Less commonly affected regions include the tail and the pinnae, and in contrast with 
Devon Rex and sphynx cats, the interdigital regions and claw folds.85,261,287 
 
Although uncommon, Malassezia overgrowth should be considered in every case of localised or generalised 
erythema associated with seborrhoea in cats.287 
 
13.2 Feline idiopathic facial dermatitis 
Feline idiopathic facial dermatitis is an uncommon skin disorder of presumed hereditary origin.400 Persian, 
and anecdotally Himalayan, cats are predisposed.400-402 Affected cats show progressive skin lesions on the 
face characterised by symmetrical erythema and exudate with black waxy material matting the distal hair 
particularly in facial folds, perioral, periocular and preauricular regions. Secondary excoriations may be 
present in severe cases. A concurrent bilateral erythematous otitis with black waxy exudate was reported in 
seven of 13 cats.400 
 
Malassezia overgrowth has been found with cytology methods in approximately half of the reported cases, 
and more often with concurrent coccoid and/or rod bacterial overgrowth.400-402 In one study five of 12 cats 
partly responded to antimicrobial agents. Of these cats, four received ketoconazole 10 mg/kg for 14-42 days 
either alone (2/4 cases) or with concurrent antibiotics (two of four cases). A partial reduction in pruritus and 
exudate was noted in three of four cats. A 2% chlorhexidine 2% miconazole shampoo three times weekly in 
one case was used to a good initial response but was subsequently withdrawn due to irritation. It was 
concluded based on the partial responses seen in some cats that concurrent infection may be a complicating 
factor in this disease.400 
 
13.3 Feline paraneoplastic alopecia 
Feline paraneoplastic alopecia is a clinically distinct disease that occurs secondary to carcinoma of the liver, 
bile duct, intestine and pancreas, as well as with a neuroendocrine pancreatic carcinoma and hepatosplenic 
plasma cell tumour.82,83,403-410 The typical clinical presentation is of ventral alopecia with inelastic, thin, 
smooth and shiny but not fragile skin; adjacent hairs can be easily epilated. Limbs, paws and ears may be 
variably affected and dry crusting and fissuring of the footpads is occasionally noted. It is a non-pruritic 
disease unless there is significant secondary Malassezia (or bacterial) infection, usually manifest by crusts 
and brown exudate.404,406-408 405,409,410 Systemic azoles (itraconazole 5-10 mg/kg once daily287 and 
ketoconazole 5 mg/kg twice daily406) have been used in a limited number of cases to successfully treat 
concurrent Malassezia infections, resulting in reduced pruritus, better quality of life and reduction of 
inflammatory changes on histopathology, albeit without improving the poor prognosis associated with 
frequently metastatic neoplasia.83,406   
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13.4 Thymoma-associated exfoliative dermatitis 
Significant colonisation of the skin with Malassezia organisms may be associated with some cases of 
thymoma-associated exfoliative dermatitis. This is a paraneoplastic syndrome characterised by a generalised 
marked inflammatory exfoliation with patchy hair loss and easily epilated hair, and variably thickened skin 
which may be fissured or ulcerated. While this disease has been reported a number of times, only two reports 
confirmed associated Malassezia overgrowth.253,411 The remaining reports could not definitively confirm the 
presence of a thymoma,83 or failed to demonstrate yeast on histopathology, though skin cytology and/or 
culture was not noted to be performed in all cases.412-415  
 
A single cat with thymoma and confirmed Malassezia overgrowth (confluent growth on contact plates) that 
was treated surgically and followed up showed no yeast growth on contact plate culture six months following 
surgical removal. The only additional treatment for the M. pachydermatis initially isolated in this time was 
two baths in a selenium sulphide shampoo, indicating a likely strong association between yeast overgrowth 
and the thymoma.253 
 
13.5 Superficial necrolytic dermatitis 
Superficial necrolytic dermatitis (syn. necrolytic migratory erythema, metabolic epidermal necrosis) has 
been very rarely reported in cats, in association with pancreatic carcinoma, thymic amyloidosis, 
hepatopathies and intestinal lymphoma.83,416-419 Clinical signs include scaling and variable alopecia of the 
trunk and limbs, with or without pruritus, and ulceration and crusting of the oral mucocutaneous junctions 
and interdigital regions. Two authors have reported secondary Malassezia dermatitis in conjunction with this 
presentation.83,420 
 
13.6 Feline acne 
Malassezia organisms have been identified with cytology methods and/or histopathology in 16% (four of 25) 
to 18% (four of 22) of reported cases of feline acne.254,421 Malassezia organisms in feline chin acne have 
been identified not only on the skin surface, but also occasionally within comedones.422 There is some debate 
over the role of the pathogenicity of Malassezia spp. in chin acne,421 although two cases were reported in 
conference proceedings which responded poorly to antibiotics, had yeast organisms on both histopathology 
and cytology samples, and showed a good clinical and mycological response to a 30 day course of oral 
ketoconazole.74  
 
13.7 Otitis externa 
Malassezia pachydermatis is the predominant Malassezia yeast isolated from cats’ ears; frequency of 
isolation is increased in cats with otitis externa.423 In addition, M. furfur has been isolated from the ear of a 
healthy cat, whereas M. sympodialis56,76,424 and M. nana 24,116 have been recovered from both healthy cats 
and cats with otitis externa. Whilst many healthy cats have ear canals apparently devoid of Malassezia 
yeasts, despite attempts to associate particular yeast counts with ear disease,425 there is a subset of cats 
which can carry large numbers of yeast in their ear canals without evidence of otitis externa.114,398,426 It has 
been suggested that the finding of excessive otic Malassezia organisms in the absence of clinical signs may 
potentially be indicative of occult systemic disease.114  
 
Some feline cases of otitis externa are associated with Malassezia yeasts as the sole pathogen,424,427,258,426 
whereas concurrent bacteria426,427 and/or Otodectes cynotis mites398,427 are commonly identified. Affected 
cats usually present with excessive dark to black waxy to flaky exudate, erythema, with variable otalgia, 
canal wall hyperplasia, pruritus and odour.79,398,424 Underlying diseases or co-morbidities include 
otoacariasis,258,398 atopic dermatitis,85,287,397 and feline idiopathic facial dermatitis,400 although some cats 
have no identified predisposing diseases.258,424 
 
Interestingly, unlike the situation in seborrhoeic basset hounds,98,145 there is no evidence for an increased 
prevalence of Malassezia otitis in seborrhoeic Devon Rex and sphynx cats prone to Malassezia 
dermatitis.80,115 
 
13.8 Conclusions: clinical presentation in cats 
Erythema, usually with kerato-sebaceous scale, and pruritus (minimal, mild, moderate or severe) dominates 
the clinical presentation. There may be concurrent otitis externa and an observed breed predilection (Devon 
rex, sphynx). Malassezia dermatitis might feature in cats that present with a phenotype of allergic skin 
disease, idiopathic facial dermatitis (Persian / Himalayan), feline acne and serious internal medical disorders 
such as feline paraneoplastic alopecia and thymoma-associated exfoliative dermatitis.  
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14. Summary of the diagnostic approach 
 
14.1 Dog or cat presents with inflammatory skin disease potentially associated  
with Malassezia yeasts (clinical features are summarised in sections 12.5 and 13.8) 
 
14.2 Establish whether Malassezia yeasts can be identified cytologically (or by quantitative 
culture using contact plates or detergent scrub; not routine swab culture) in lesional areas. 
Counts may be high but not necessarily so.  
 
YES  Initiate trial therapy with appropriate topical and or systemic antifungal product. 
NO Sample more sites; use an alternative sampling method; reconsider diagnosis. 
 
Additional diagnostic evaluations and treatments may be indicated at first presentation depending on the 
clinical signs, including cases where signs suggest, for example, paraneoplastic disorders in cats.  
 
14.3 Evaluate the clinical and mycological response to appropriate topical (three to four weeks) 
and or systemic (two to four weeks) antifungal therapy 
 
 COMPLETE CLINICAL & MYCOLOGICAL RESPONSE - diagnose Malassezia dermatitis; consider an 
underlying cause. 
 PARTIAL CLINICAL, COMPLETE MYCOLOGICAL - diagnose Malassezia dermatitis; investigate/treat 
ongoing underlying skin disease.  
 NO CLINICAL RESPONSE, COMPLETE MYCOLOGICAL - consider yeast presence incidental to other 
inflammatory disease.  
 PARTIAL CLINICAL & MYCOLOGICAL RESPONSE - suspect Malassezia dermatitis; review compliance; 
extend or intensify antifungal therapy.  
 NEITHER CLINICAL OR MYCOLOGICAL RESPONSE - review compliance; consider abnormal drug 
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15. Therapy 
 
15.1 General considerations 
Treatment of Malassezia dermatitis typically involves the use of topical and/or systemic antifungal 
medications.393 Topical treatments such as shampoos, gels and lotions are appropriate for Malassezia 
dermatitis since the yeast is located within the stratum corneum. Shampoos are particularly interesting 
because they have a mechanical action that may reduce scaling and greasy exudation; some are formulated 
with keratoregulating agents such as phytosphingosine, ammonium lactate, zinc gluconate and salicylic 
acid.428 Although some clinicians favour other topical formulations and combinations (such as mousse, wipes, 
sprays, particularly in skin folds), these products currently require further evaluation to justify their 
therapeutic recommendation.  Systemic therapies are often more expensive than topical therapies but may 
be necessary in cases where topical therapy is challenging for the owner / patient affiliation or otherwise 
ineffective. However, a combined topical / systemic approach may be optimal in some dogs with generalized 
and/or severe lesions: one study (published in abstract form) showed that a combination or oral 
ketoconazole and 2% miconazole /2% chlorhexidine shampoo was more effective and allowed a better speed 
of cure than either topical or systemic treatment used alone.429 It is also important to diagnose and treat 
the underlying cause responsible for the proliferation of the yeast (section 7).  
 
15.2 Development of the consensus on therapy 
Many in vitro studies have been published showing the potential activity of various molecules against yeast 
and notably Malassezia spp. (reviewed in section 10). Unfortunately trials assessing the in vivo efficacy of 
antifungal treatment for Malassezia dermatitis in dogs are few in number and commonly involve only small 
group sizes with resultant low statistical power. This is quite surprising if we consider that Malassezia 
dermatitis is a very common condition in veterinary medicine. In cats data are even less numerous and only 
open studies have been reported.  
 
The authors approached the development of consensus guidelines on therapy on two levels. Firstly, we 
performed a systematic search and review of relevant published trial data with grading of the study quality 
to provide evidence based conclusions on the strength of recommendation, updating a previous review.430 
Secondly, we provided summary practice guidelines that are primarily evidence-based and drawn from part 
one and included a component of expert opinion where the evidence based data is limited or absent. Thus, 
our concluding summary falls between the definitions of “Practice Guideline (Evidence-Based)” and “Practice 
Guideline (Consensus)”.2  
 
For the systematic review we utilised the Strength of Recommendation Taxonomy (SORT), a comprehensive 
taxonomy for evaluating the strength of recommendation based on a body of evidence and the quality of 
individual studies (Table 2).2 This schedule emphasises the use of patient-oriented outcomes and is designed 
to simplify the interpretation of studies and facilitate their incorporation into evidence-based patient care. 
Studies for review were identified by electronic searches of the PubMed (National Center for Biotechnology 
Information, US National Library of Medicine 8600 Rockville Pike, Bethesda MD 20894, USA) and CAB Direct 
(Centre for Agriculture and Bioscience International, Wallingford, UK) databases (keywords were Malassezia, 
treatment, dog, cat) and manual searches of Advances in Veterinary Dermatology, Volumes 1- 8 (no relevant 
studies identified). The studies were included if presented in full or abstract form in a peer-reviewed journal; 
studies presented only in conference proceedings were not evaluated due to likely infrequent availability to 
the wider veterinary dermatology community.  
 




In spite of the widespread practice use of ketoconazole to treat Malassezia dermatitis, only a few studies 
evaluated the efficacy of this azole in vivo. Studies were either randomized and controlled,146,383,429,432 or 
controlled without blinding433 (Table 3) involving relatively small group sizes (7-12 dogs). Together, these 
studies indicated that the use of ketoconazole at an oral dosage of 5-10 mg/kg/day is most often either 
completely or partially effective, when given fasted, to improve both clinical signs and cytological or colony 
counts from dogs suffering from Malassezia dermatitis (Strength of Recommendation (SoR) B-moderate). 
The length of treatment varied between three and four weeks in most cases. Whilst one un-blinded 
randomised study of 20 dogs suggested that there was no significant difference in efficacy between 5 and 
10 mg/kg/day of ketoconazole administrated once daily for three weeks,433 there is insufficient evidence to 
comment specifically on the efficacy of the various doses used (5 or 10 mg/kg, once or twice daily). Reports 
of improved efficacy with KTZ at doses of 10 mg/kg twice daily391 do not appear to have been subjected to 
critical comparative trials. Adverse reactions are regularly reported with the use of ketoconazole in dogs; a 
retrospective study of 632 dogs that received a median daily dose of 10 mg/kg reported adverse effects in 
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14.6%, including primarily vomiting (7.1%), anorexia (4.9%), lethargy (1.9%) and diarrhoea (1.1%).434 
Adverse effects were significantly more frequent in dogs receiving concurrent ivermectin or ciclosporin. 434  
  
15.3.2 Itraconazole 
Itraconazole appears to be effective based on the few clinical trials that have evaluated its efficacy for the 
treatment of canine Malassezia dermatitis432,435 (Table 4; SoR B-moderate). Two were comparative versus 
ketoconazole. Therapeutic doses recommended are variable with 5 mg/kg once daily, or for two consecutive 
days a week, being most often used. In two relatively small studies there were no significant differences in 
any results between itraconazole pulse therapy (two days on, five days off) and the daily administration of 
either itraconazole or ketoconazole.432,435 The pulse therapy approach reflects predicted accumulation of this 
lipophilic drug in the stratum corneum436 and reduces costs and likely also side-effects of this relatively well-
tolerated azole. Adverse effects seem to be less frequent with itraconazole compared to ketoconazole: 
transient vomiting and decreased appetite were relatively rare in the published studies (four of 49 cases).  
 
15.3.3 Fluconazole 
Only one study evaluated the use of fluconazole for the treatment of Malassezia dermatitis in dogs.383 This 
double-blind randomized controlled study comprising 25 dogs showed that fluconazole at 5-10 mg/kg orally 
once daily administered with food was as effective as ketoconazole at 5-10 mg/kg orally once daily for 
controlling the clinical and cytological signs of Malassezia dermatitis (Table 5). Concurrent use of cefalexin 
in both treatment groups limits full clinical interpretation (Level of Evidence [LoE] 2; SoR B-moderate). 




One study showed that oral terbinafine at 30 mg/kg orally once daily for 21 days reduced yeast counts 
(assessed by contact plates) in a group of seven basset hounds with high skin population densities of M. 
pachydermatis but without dermatitis; mycological efficacy was numerically but not statistically inferior to 
oral ketoconazole at 10 mg/kg once daily.284 This low-powered study was not included in the SORT analysis 
because the outcome is disease-orientated (yeast count) rather than patient-oriented (no clinical scoring) 
(LoE 3).2 The efficacy of terbinafine was subsequently assessed in two clinical trials, either randomized and 
controlled by a different interval of dosing of terbinafine, or in a small study with concurrent cefalexin therapy 
(Table 5; SoR C-weak).146,437 Monitoring of serum hepatic enzymes has been recommended for dogs 
receiving daily oral terbinafine in view of reports of reversible, mild-moderate elevations of alanine 
aminotransferase and serum alkaline phosphate.437,438 A study designed to integrate pharmacokinetic data 
with previous MIC data in 10 healthy dogs treated with 30 mg/kg orally once daily for 21 d indicated that 
terbinafine does not achieve high stratum corneum and sebum concentrations compared with serum values; 
achieved concentrations barely exceeded previously reported in vitro MIC values.354 These and other 
pharmacokinetic data might indicate preferential utility for systemic mycoses,439 or the need for further dose 
optimisation for superficial mycoses in dogs.  
 
15.4 Review of trial data in dogs: topical treatments 
15.4.1 Miconazole and chlorhexidine 
Miconazole is an azole derivative present in various shampoos, creams or lotions. A combination of 2% 
miconazole and 2% chlorhexidine in a shampoo formulation is licensed for the treatment of canine Malassezia 
dermatitis in a number of countries, primarily in Europe and Australia. Consistent high efficacy has been 
reported in randomised controlled trials (RCT) (Table 6; SoR A–strong). In one RCT study, clinical efficacy 
was associated with marked reductions in skin population densities of both M. pachydermatis and total 
bacteria / staphylococci, assessed using a detergent scrub technique.145 In the second RCT, yeast counts 
were assessed by tape-strips whereas bacterial populations were not assessed.271 Adverse effects to 
miconazole / chlorhexidine were not reported amongst the 48 dogs treated in these two studies,145,271 
although the UK data sheet of the product used mentions ‘very rare’ or ‘exceptional’ pruritic or erythematous 
reactions (http://www.noahcompendium.co.uk/?id=-449936). 
 
15.4.2 Other chlorhexidine products 
In a RCT, a 3% chlorhexidine shampoo was reported to be more than 50% effective in 18 of 22 treated 
dogs271 (Table 6; LoE 1; SoR B-moderate) and was judged not inferior to 2% miconazole and 2% 
chlorhexidine. Four dogs had transient and self-limiting side effects; the UK data sheet reports that self-
limiting pruritus and erythematous reactions are ‘common’ and that conjunctival inflammation may occur. A 
3% chlorhexidine and 0.5% climbazole shampoo was compared with a 2% miconazole and 2% chlorhexidine 
shampoo in a blinded design in 16 basset hound dogs (seven healthy, nine greasy) by a single application 
of each product to one side of the body.440 Both yeast counts (by contact plates) and clinical scores reduced 
during the fourth day trial period but clinical interpretation was limited by the varied clinical status of the 
subject dogs in this published abstract (LoE 3).  
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15.4.3 Miconazole 
A small RCT of 1% and 2% miconazole conditioners of low statistical power showed reductions in clinical 
scores and yeast counts but no statistical difference when compared with vehicle control (LoE 2).441   
 
15.4.4 Climbazole 
A 2% climbazole shampoo had rapid mycological efficacy in a small disease-oriented (contact plate yeast 
count) rather than patient-oriented (no clinical scoring) RCT involving six treated and five control beagle 
dogs without skin lesions (SoR not applicable).285 Similarly, a short, open study of wipes containing 0.5% 
climbazole, 0.3% chlorhexidine and Tris-EDTA assessed only yeast counts but not clinical parameters.286  
 
15.4.5. Enilconazole 
A 0.2% enilconazole lotion is licensed in some countries for the topical therapy of dermatophytosis in dogs, 
cattle and horses. Only one retrospective study of 12 cases of generalised Malassezia dermatitis reported 
treatment with a 0.2% enilconazole lotion (frequency of application not detailed) in association with oral 
ketoconazole.442 Although a complete mycological recovery was described, no specific report of clinical 
improvement was available (LoE 3; SoR not applicable).  
 
15.4.6. Others 
In a RCT involving 35 dogs, 20 received a commercially-available mixture of essential oils (Malacalm, Flora 
Slr Oli essenziali, Lorenzana, Italy) twice daily for one month, 10 received oral ketoconazole 10 mg/ kg orally 
once daily and 2% chlorhexidine twice weekly and five dogs served as untreated controls.443 Whilst the 
authors reported a >50% improvement in clinical scores in nine of 10 of dogs treated with essential oils, 
and in all of the dogs treated with ketoconazole and chlorhexidine, interpretation is limited by unclear 
randomisation and blinding procedures, and failure to report pre- and post-treatment group clinical scores 
(mean or median, range) in the three treatment groups (LoE 2; SoR C-weak). An unusual feature of this 
study was reported lack of relapse 150 days post-treatment in all of the essential oil-treated dogs. Further 
evaluation of this product is warranted.  
 
Selenium sulphide, piroctone olamine, benzalkonium chloride, triclosan formulated either in gels, shampoos, 
lotions, sprays or spot-on are also available but there is insufficient evidence to recommend their use at this 
time. In an open case series published in abstract form, a shampoo combination of piroctone olamine and 
ammonium lactate and a lotion (piroctone olamine and salicylic acid) reduced clinical scores and cytological 
yeast counts in 14 seborrhoeic dogs with high Malassezia counts (LoE 3);444 these data should be confirmed 
in a RCT.   
 
15.5 Review of trial data in cats 
In cats only open case series have been described, using oral itraconazole at varying doses and intervals 
(Table S7, LoE 3, SoR C-weak).85,86,287 As for dogs, topical antifungal agents such as miconazole, 
chlorhexidine or climbazole are likely to be beneficial but there is no data to substantiate this, other than 
anecdotal reports.  
 
15.6 Antifungal drug formulation  
The relatively high cost of certain innovator-formulated drugs such as itraconazole has stimulated the 
compounding of bulk powder formulations by pharmacists in an attempt to reduce costs to clients. This is 
legal in some (but not all) countries under certain conditions. In a randomised cross-over study involving 
nine healthy beagle dogs, neither generic nor compounded itraconazole was bioequivalent to the innovator-
formulated product.445 Pharmacokinetic analyses showed that the compounded formulation had very low 
absorption and bioavailability (5% of innovator product), yielding likely ineffective plasma concentrations, 
whereas the generic and reference products were broadly similar to each other. In a similar study of eight 
healthy cats, itraconazole compounded in both capsules and suspension was absorbed poorly and 
inconsistently.446 In a field study of 95 dogs and 20 cats receiving either compounded, generic or innovator-
formulated itraconazole for systemic mycoses, sub-therapeutic concentrations were detected in 95.2% of 
animals receiving the compounded formulation but in only 12.5% or less of the animals treated with generic 
or reference formulations.447 The poor bioavailability of itraconazole in compounded formulations and in 
some cases treatment failures, has been attributed to the absence of cyclodextrin, a carrier compound shown 
to improve gastro-intestinal absorption.448,449 A study of compounded fluconazole suspensions showed poor 
pharmaceutical accuracy (median 74% of target concentration).450 These data indicate that compounded 
azole formulations must not be used; innovator-formulated or proven generic formulations are preferred.  
There appears to be no published data on the comparative efficacy of different topical formulations 
containing the same or similar ingredients. This may be especially relevant with over-the-counter 
formulations where regulatory assessment of product quality may be less exacting and with molecules such 
as chlorhexidine whose stability may vary under different conditions.451 Both published RCT of a 2% 
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miconazole and 2% chlorhexidine shampoo with strong evidence of efficacy utilised the same innovator-
formulated licensed product (Malaseb, Derm-care Vet, Slacks Creek, Queensland, Australia);145,271 one of 
these studies also showed good activity from a licensed 3% chlorhexidine shampoo (Microbex®, VIRBAC 
SA, Carros, France).271 
 
15.7 Conclusions: consensus guidelines for treatment of Malassezia dermatitis in dogs and cats. 
Amongst the various treatments utilised for Malassezia dermatitis in dogs, strong evidence (SoR A) is 
available only for the use of a 2% miconazole and 2% chlorhexidine shampoo, used twice weekly (two RCT 
with LoE 1). This may be considered to be the topical treatment of first choice, where available and locally 
approved, and when owners are able to apply the product effectively. Moderate evidence (SoR B) is available 
for a 3% chlorhexidine shampoo (a single study of LoE 1). 
 
For canine Malassezia dermatitis, there is moderate evidence (SoR B) for the use of ketoconazole at 5-10 
mg/kg orally once or twice daily (five studies of LoE ≥2); and itraconazole at 5 mg/kg orally once daily or 
two consecutive days per week (two studies of LoE ≥2). Based on current limited evidence, the use of either 
of these two azoles is justified in canine cases and the final choice may depend on regional differences in 
availability, regulatory status and cost. Rationale for itraconazole instead of ketoconazole includes the 
potential for intermittent dosing and a perceived tendency for itraconazole to be better-tolerated. However, 
definitive statistical evidence of superior safety and/or efficacy is lacking and cost-benefit analysis makes 
ketoconazole a more practical choice in some countries. Compounded formulations must be avoided due to 
unreliable bioavailability.  Evidence for fluconazole is limited to a single study (LoE 2) where it was used at 
5-10 mg/kg orally once daily in conjunction with cefalexin. Thus fluconazole requires further assessment, 
especially since in vitro MIC values are routinely the highest amongst antifungal azoles utilised in veterinary 
medicine (section 10); this may correlate with intermittent anecdotal reports of treatment failures. 
Terbinafine warrants further evaluation due to partial beneficial effects in two trials (SoR C-weak) and 
questionable stratum corneum concentrations in a pharmacokinetic study when given at the current dose of 
30 mg/kg orally once daily.  
 
In cats, there is weak evidence only (SoR C) for the use of itraconazole at doses of 5-10 mg/kg orally once 
daily; or 5 mg/kg on a seven days on / seven days off protocol. In view of this limited data, good safety 
profile and in line with guidelines for feline dermatophytosis,1 itraconazole should be considered as the 
systemic azole of first choice in this species for Malassezia dermatitis. Topical chlorhexidine and azole 
products have not been evaluated although their use is intuitive as adjunctive or sole treatments where 
application is practicable and clinically appropriate, such as in localised infections. 
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16. Prevention of Malassezia-associated skin diseases in dogs and cats 
 
16.1 Management of underlying diseases 
As Malassezia yeasts are part of the normal cutaneous microflora, complete elimination of the organism is 
unrealistic even with effective treatment.452 Relapsing infections are common where there is persistence of 
the underlying cause for the yeast overgrowth. The standard clinical approach is identification and treatment 
of underlying causes, whenever possible,393,396,452-454 though there is surprisingly limited reported evidence 
to document its efficacy (Table S8).  
 
16.2 Topical therapy 
When predisposing factors cannot be identified or controlled in an animal suffering from recurrent Malassezia 
infections, regular topical or pulsed oral antifungal therapy have been recommended to minimise the 
frequency of infection relapses that cannot be managed by other means.396,452,455  
 
Multiple topical therapies have been shown to be effective for treatment of Malassezia dermatitis in dogs 
and cats (section 15). In addition, because of a lower risk for toxicity, topical treatments have also been 
recommended (if practical and not causing irritation431,455) as preferable to systemic treatments for long-
term therapy in chronically relapsing cases.453 Furthermore, there is evidence that bathing dogs in 2% 
chlorhexidine / 2% miconazole shampoo every three days can reduce oral carriage of Malassezia 
organisms.99 However, recommendations for weekly antifungal shampoo bathing as a preventive strategy 
to reduce the frequency of recurrent Malassezia dermatitis appear anecdotal rather than evidence-based.452 
Studies in vitro that demonstrate shampoo persistence on hairs may or may not be relevant to persistence 
on skin,453 and studies in vivo on topical therapy persistence were conducted in normal dogs rather than in 
dogs with Malassezia dermatitis.285,286  
 
In a comparative study of a commercial mixture of essential oils (Malacalm; Flora s.r.l., Lorenzana, Pisa, 
Italy) applied twice daily for one month to 20 dogs with recurrent Malassezia dermatitis, and combined 
ketoconazole (10 mg/kg orally once daily) and 2% chlorhexidine shampoo (twice weekly) for 21 days in 10 
dogs, both groups showed good clinical and cytological improvements at day 30.443 When reviewed at day 
180, all conventionally treated dogs had reportedly relapsed whereas dogs treated with the essential oil 
formulation had not.443 Interpretation of this study is limited by incomplete randomisation, clinical and 
cytological data in the publication and an absence of within and between-group statistical comparisons at 
day 180-time point; consequently this treatment cannot be recommended for prevention without further 
critical assessment. 
 
With respect to prevention of recurrent Malassezia otitis, while studies in vitro have demonstrated 
antimicrobial efficacy of ear cleaners,456,457 there are only two studies examining topical therapy for 
prevention of Malassezia otitis. A single study examining dogs with recurrent allergic otitis showed a 
favourable outcome to a once weekly ear cleaner containing chloroxylenol and cerumenolytics (Epiotic, 
Virbac Carros, France) and concurrent twice weekly three drops per ear of 0.0584% topical hydrocortisone 
aceponate solution (Cortavance, VIRBAC SA, Carros, France) (95% chance of remaining free of relapse at 
day 180) compared with weekly ear cleaner alone (50% chance of remaining infection free at day 180).458 
However, the lack of detail regarding the nature of the infection for both pre-treatment and relapsing otitis, 
makes a recommendation specifically for the prevention of Malassezia otitis difficult. A second open study 
examining twice weekly 2% acetic acid 2% boric acid topically showed the protocol unsuccessful in 
preventing relapse of Malassezia otitis beyond previously documented relapse intervals in six of eight 
cases.459  
 
16.3 Pulsed oral antifungal therapy 
Oral antifungal drugs might be given by an intermittent / pulsed dosing schedule to try to prevent recurrent 
Malassezia dermatitis (and otitis) in dogs and cats, particularly where topical therapy is either ineffective or 
impractical. Overall, published evidence that substantiates the efficacy of this approach is lacking. Whilst 
the clinical risk appears low, it should be noted that intermittent use of oral antifungal drugs could potentially 
predispose to development of antifungal resistance (section 11).355,385 A dosing regimen of two consecutive 
days per week (“weekend therapy”) has been investigated or proposed for three oral antifungal drugs. 
Terbinafine (30 mg/kg orally once daily, two days on / five days off) reduced yeast counts in tape-strips 
from dogs with Malassezia dermatitis but clinical resolution was considered complete in only one of 10 dogs 
at the end of 21 days.437 Whether pulse therapy with terbinafine might prevent relapse of previously resolved 
infections remains to be determined, but doubts over skin concentrations achieved with current doses354 
makes use of this drug questionable.  
 
Pulsed therapy with itraconazole (5 mg/kg orally once daily, two days on / five days off for three weeks) has 
been shown to be efficacious in the treatment of Malassezia dermatitis in dogs435 and thus should be effective 
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as a preventative, although one report highlighted  potential for development of antifungal drug resistance 
with pulse dosing (section 11.5.2385). By contrast, this regimen was not fully effective at reducing otic counts 
of Malassezia and therefore pulsed dosing cannot currently be recommended for prevention of otitis externa. 
There are only anecdotal reports of preventative efficacy of itraconazole for dermatitis at a once-weekly 
interval. Ketoconazole (5-10 mg/kg orally once daily, two consecutive days per week) has also been 
recommended anecdotally without any published studies at this dose,452 although itraconazole is generally 
regarded as being a safer drug (section 15).  
 
16.4 Malassezia Allergen-Specific Immunotherapy  
Hyposensitisation to Malassezia by immunotherapy was initially proposed in 1998 as an alternative to 
extended or repeated administration of antifungal drugs in dogs with recurrent Malassezia dermatitis with 
demonstrated IgE to Malassezia antigens.246 In a non peer-reviewed report on Malassezia immunotherapy 
(aqueous extract, 1,000 PNU weekly, Greer Laboratories, Lenoir, GA, USA) added to conventional 
immunotherapy for other allergens in four dogs with atopic dermatitis still prone to recurrent Malassezia 
dermatitis, results were reported as good to excellent in all cases.460 A retrospective study reported a good 
response to subcutaneous alum-precipitated immunotherapy (Artuvetrin®, 100 g/mL, ArtuVet Animal 
Health BV, Lelystad, Netherlands) using 1 mL per month (dose adjusted if required based on clinical 
response) for a minimum of 10 months. Nine of 16 Malassezia mono-sensitised dogs had an observed 
reduction in use of both anti-inflammatory and antifungal medication, as well as a >50% reduction in pruritus 
scores.461 However, despite the improvement noted in both studies, the quality of evidence remains low and 
the significance of >50% improvement of pruritus is disputable as a meaningful measure of success.462 
Further studies are required to better assess the potential benefits of Malassezia allergen-specific 
immunotherapy as a preventative approach.   
 
16.5 Conclusions  
When predisposing factors cannot be controlled, regular treatment is often required to minimise relapses. 
Topical treatments are preferred to systemic treatments for long-term therapy because of a lower risk of 
toxicity. Topical prevention of Malassezia dermatitis in dogs might be achieved using 2% chlorhexidine / 2% 
miconazole or 3% chlorhexidine shampoo twice weekly, as has been previously recommended for treatment. 
Lesser frequencies may be useful in preventing relapse in some cases but there is currently no evidence to 
support this. Twice weekly topical hydrocortisone aceponate shows promise in the prevention of Malassezia 
otitis externa associated with allergic skin diseases. Pulsed therapy with itraconazole (5 mg/kg orally once 
daily, two days on / five days off for three weeks) has been shown to be efficacious in the treatment of 
Malassezia dermatitis (but not otitis externa) in dogs and thus should be effective as a preventative, although 
one report has highlighted potential for development of antifungal drug resistance with pulse dosing. There 
are only anecdotal reports of preventative efficacy of itraconazole for dermatitis at a once-weekly interval.    
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17 Malassezia yeasts as zoonotic agents 
 
17.1 Background 
Characterizing the zoonotic potential of pathogenic agents is always a difficult task. The concomitant 
presence of the same species or the same genotypes in humans and animals is a first indication but of course 
it is not absolute proof unless transmission from one host to another has been clearly demonstrated. The 
case of Malassezia yeasts is rather complex because many of the 18 currently described species have been 
found on the skin of animals as well as of humans (Table 1). 
 
17.2 Skin colonisation in humans 
Several species of Malassezia yeast are known to colonize healthy people as part of the commensal 
microbiome of human skin.33,121,463,464 Spatial distributions of the species most commonly identified (M. 
globosa, M. sympodialis and M. restricta) may vary according to the age, body site and geographical location 
of the subjects studied.88,121,465 The archetypal zoophilic species, M. pachydermatis, may also be isolated 
from healthy human skin by culture or detected by molecular techniques, especially from the face465,466 and 
hands.466,467 In a retrospective study of 32 Malassezia spp. isolates from human clinical specimens collected 
in 1984 at the Center for Disease Control in Atlanta (USA) 15 were identified as M. pachydermatis.468 These 
last isolates were mainly from skin, tissue fluids (e.g. eye, ear, vagina) and four were isolated from blood. 
Skin colonization by Malassezia species in full term healthy newborns has been also investigated.469 
Malassezia pachydermatis was not isolated from the skin of human neonates, while M. sympodialis and M. 
globosa colonisation begins at birth and increases in the first weeks of life.  
 
17.3 Genotyping 
In epidemiological studies, genotyping of Malassezia yeasts may be required in order to identify the source 
of infection and to discover possible connection of genotypes with particular diseases. Different studies 
targeted various RNA or DNA regions in order to distinguish the molecular pattern of M. pachydermatis and 
to assess whether genotype classification was in accordance with host preferences. In one of these studies, 
the partial sequencing or large subunit rRNA in one hundred isolates resulted in the differentiation of seven 
different haplotypes, namely Ia, Ib, Ic, Id, Ie, If, Ig.303 Haplotypes Ic, Id and Ig seemed to be specific to 
one animal species (rhinoceros, dogs and ferrets, respectively). Isolates from humans all belonged to 
haplotype Ia which was also detected in animals (especially dogs and cats). More recently, the spectrum of 
fungal species (“mycobiome”) in the human skin was investigated using next generation sequence 
techniques.121 In this study, 14 skin sites representing a range of physiological characteristics were sampled 
from 10 healthy adult volunteers. Malassezia yeasts predominated on most of the sampled body sites and 
11 Malassezia species (including M. pachydermatis) were directly identified by rRNA gene sequencing from 
the different clinical samples.  
 
17.4 Isolation of Malassezia pachydermatis from humans 
Pathogenic roles for various Malassezia species have been described in association with several human skin 
diseases including atopic dermatitis, seborrhoeic dermatitis, folliculitis, psoriasis and pityriasis 
versicolor.88,464 Among these diseases, M. pachydermatis has been most commonly isolated from human 
patients with seborrhoeic dermatitis.465,470,471 However, it is difficult to assign a truly pathogenic role to M. 
pachydermatis in the context of these studies and its identification from surface samples of human skin is 
typically ascribed to contact with dogs (even though epidemiological data on pet contact is not always 
available). One exception has been the report of a facial granuloma in a dog owner, where M. pachydermatis 
was identified by electron microscopy in affected tissues, the yeast was grown and identified by standard 
microbiological methods and the patient responded to anti-fungal therapy.472 
 
Malassezia pachydermatis has also been isolated with significantly higher prevalence from the sputum of 
asthmatic human patients (21.7%) than from healthy controls (0%).473 The clinicopathologic significance of 
this finding, if any, is unknown and data on pet ownership was not collected from the subjects studied. 
 
17.5 Zoonotic aspects 
From a zoonotic perspective, the pathogenic role best documented for M. pachydermatis is a syndrome of 
life-threatening fungaemia that occurs in pre-term neonates while receiving lipid-rich nutritional infusions 
via catheter.474-480 Malassezia furfur is the primary skin-colonizing species of human infants481 and is 
therefore the species most commonly implicated in this syndrome;482 however M. pachydermatis has also 
been clearly documented as an aetiological agent.474 For example, an epidemiological investigation of an 
outbreak occurring in a neonatal intensive care unit (NICU) identified a single strain of M. pachydermatis – 
as determined by pulsed-field gel electrophoresis – which was isolated from 15 infants with sepsis, nine 
colonized infants, the hands of a nurse and three dogs owned by other health care workers in the NICU.474 
In another study, 47 out of 86 M. pachydermatis isolates collected from 25 neonatal patients at a French 
University Hospital were genotyped using intergenic-spacer 1 nucleotide sequence polymorphisms 
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analysis.476 All 47 isolates clustered within sequence type 3 (most of them clustered within the 3D subtype, 
the remaining clustered within three newly described subtypes: 3E, 3F and 3G). No particular subtype was 
associated with a collection site or a particular time-period but multiple genotypes could colonize the same 
neonatal patient. The outbreak resolved upon implementation of infection control measures, including 
withdrawal of lipid-rich hand moisturisers from staff. In addition to this neonatal syndrome, M. 
pachydermatis has been implicated in severe systemic infections of immunocompromised adult 
patients.483,484   
 
In a study designed to estimate the prevalence of M. pachydermatis hand carriage by dog owners, two 
groups of people were sampled by culture and PCR techniques: owners of 50 healthy dogs and owners of 
75 atopic dogs with cytological evidence of Malassezia dermatitis and/or otitis.467 When detection rates by 
hand culture were compared, owners of affected dogs were 11 times more likely to be positive for yeast 
isolation than owners of healthy dogs. However, there was no difference between groups when the highly 
sensitive PCR technique was utilized, as greater than 90% (70 of 75) of owners in each group had detectable 
hand carriage.467 This study served to underscore the importance of good hand hygiene by health care 
professionals in whom mechanical carriage of many ubiquitous opportunistic pathogens is possible. Very 
little is known about hand washing agents and techniques (contact time etc.) that will effectively eliminate 
carriage of Malassezia yeasts from human hands. However, it is known that both chlorhexidine and 
polyhexanide have excellent in vitro activity against M. pachydermatis.485 In addition, improved hand-
washing practices eliminated an endemic problem with M. pachydermatis infections in a NICU.474  
 
17.6 Conclusions 
Given the high prevalence of M. pachydermatis hand carriage by dog owners (as assessed by PCR)467 and 
the relative rarity of serious human infections by this organism, it may be surmised that the overall risk for 
zoonosis is quite low, especially among people who are not severely immunocompromised. The need for 
good hand hygiene by individuals in contact with pet dogs and cats should be emphasised.  
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Figure legends 
 
Figure 1 The numbers of publications on Malassezia pachydermatis by year (a) and for dogs (b) and cats 
(c) from 1900 to present day.  
 
Figure 2 Transmission electron micrograph of Malassezia pachydermatis.  
 
Cells have a thick cell wall with characteristic inner spiralling. Monopolar blastic development is associated 
with a prominent bud scar. Scale bar = 500 nm. 
 
Figure 3 Tape-strip impression from the lip fold of a dog with Malassezia pachydermatis dermatitis.   
Abundant ovoid to short cylindrical yeast cells with broad-based budding amongst squames; modified 
Wright-Giemsa stain (“Diff-Quik”), x50.   
Figure 4  Malassezia dermatitis in the neck fold of a bull mastiff.   
There is a localised and demarcated area of focally intense erythema of thickened skin, with mild alopecia 
and kerato-sebaceous material matting the remaining hairs. 
Figure 5 Malassezia paronychia in a dog characterised by brown discoloration of the proximal claw.   
Figure 6 Malassezia dermatitis affecting the axillae of an atopic West Highland white terrier.   
 
The chronic lesions are characterised by symmetrical areas of intense hyperpigmentation, severe 
lichenification, erythema and tightly adherent crust.   
 
Figure S1 Schematic structure of the ribosomal RNA gene in fungi 
Figure S2 Sequencing identification for biological classification level in fungi on each rDNA region 
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HS (dogs, cats, 
others) 




P. pachydermatis,  
P. canis 
HS + LS (dogs, 
cats, many others, 
mostly canids) 
HS (dog contact), 
fungaemia 
M. sympodialis 
1990, Simmons & 
Guého19 
M. furfur serovar A HS, OT (cats) HS, AD, SD 
M. globosa 
1996, Midgley, Guého 
& Guillot20 
P. orbiculare 
M. furfur serovar B 
HS, OT (cats) HS, PV, SD, AD 
M. obtusa 
1996,  Midgley, Guillot 
& Guého20 
 ─ HS, LS 
M. slooffiae 
1996, Guillot, Midgley 
& Guého20 
 




1996, Guého, Guillot & 
Midgley20 
M. furfur serovar C ─ HS, SD 
M. dermatis 2002, Sugita et al.21  ─ HS, AD 
M. japonica 2003, Sugita et al.22  ─ HS, AD, SD 
M. nana 2004, Hirai et al.24  
HS (cats, horses), 
OT (cats, cattle) 
─ 
M. yamatoensis 2004, Sugita et al.23  ─ HS, SD 
M. caprae 
2007, Cabañes & 
Boekhout314 
 HS (goats) ─ 
M. equina 
2007, Cabañes & 
Boekhout314 
M. equi HS, LS (horses) ─ 
M. cuniculi 
2011, Cabañes & 
Castella26 





 ─ HS, SD 
M. brasiliensis 2016, Cabañes et al. 28  HS (parrots) ─ 
M. psittaci 2016, Cabañes et al. 28  HS (parrots) ─ 
M. vespertilionis 2018, Lorch et al.29  HS (bats) ─ 
 
─ not reported; AD atopic dermatitis; HS healthy skin; LS lesional skin; PV pityriasis versicolor; SD seborrhoeic dermatitis; 
OT otitis.    
Table 2 a) The Strength of Recommendation Taxonomy (SORT) 
(b) descriptors for Levels of Evidence (LoE) for individual studies 
 
Strength of Recommendation Definition2 
A - Strong Based on consistent and good quality patient-oriented evidence 
B - Moderate Based on inconsistent or limited quality patient-oriented evidence 





Level of Evidence Definition for treatment studies2 
1 – Good quality patient-oriented High quality individual RCT, or meta-analysis of consistent RCTs 
2 - Limited quality patient-oriented Lower quality clinical trial, cohort study, case-control study 
3 – Other evidence Recommendation based on consensus, usual practice, disease-oriented 
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Table 3. Clinical trials of oral ketoconazole in the treatment of canine Malassezia dermatitis in 
dogs 
 





















Small group sizes; two 
KTZ doses compared 
2 








4/7 >50 % 
clinical 
improvement 

















Nil Small group sizes; 
compared to pulse ITZ 
2 







improvement at 6 
weeks 
Not specified Abstract publication 
only; compared to 
shampoo alone or 


























Compared with FCZ. 
2 
 
FCZ fluconazole; ITZ itraconazole; KTZ ketoconazole; LoE level of evidence; RCT-B randomised controlled trial – blinded; 
RCT-UB randomised controlled trial – unblinded.  
Table 4.  Clinical trials of oral itraconazole in the treatment of canine Malassezia dermatitis 
 
Study Design Dose used Clinical outcome Adverse effects Comment LoE 
Pinchbeck et 




5 mg /kg once 





score reduced by 
60% (pulse) and 
31% (daily) 
Nil Small group sizes; two 
ITZ intervals compared 
2 






5 mg/kg once 
daily 
All responded fully 
by d22 
Nil Combined with twice 
weekly selenium sulphide 
shampoo. No statistical 








5 mg/kg once 










Small group sizes; 
compared with KTZ 
2 
 
ITZ itraconazole; KTZ ketoconazole; LoE level of evidence; RCT-B randomised controlled trial – blinded; RCT-BNS 
randomised controlled trial – blinding not specified 
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Table 5.  Clinical trials of oral fluconazole and terbinafine in the treatment of canine Malassezia 
dermatitis 
 




Fluconazole RCT-B (13 dogs 




8/13 >50 % 
clinical 
improvement 
6/13 dogs: transient 
vomiting [n=4], 
vomiting and soft stool 













30 mg/kg  
once daily 
3/8 >50 % 
clinical 
improvement 













30 mg/kg  
once daily  
OR on two 
consecutive 
days/week, 




in both groups 
Mild signs in 3/10 dogs 
in both groups (overall 
6/20); vomiting [n=2], 
diarrhoea [n=2], 
anorexia [n=1], 
panting [n=1].  
Elevated ALT in 1 dog.  
Small group 
sizes.    Complete 
clinical resolution 
in only 3/20 dogs 




ALT, alanine aminotransferase; KTZ, ketoconazole; LoE, level of evidence; RCT-B, randomised controlled trial – blinded. 
Table 6.  Clinical trials of 2% miconazole / 2% chlorhexidine and 3% chlorhexidine shampoos in 
the treatment of canine Malassezia dermatitis 
 
Study Product Design Frequency  Clinical outcome Adverse effects Comment LoE 
Bond et al. 
1995145 


















Maynard et al. 
2011271 







Twice weekly Good (≥50%) 
response in 91% 
of dogs 

















        








for 2 weeks, 
then twice 

















CH 3% chlorhexidine; LoE level of evidence; MC-CH 2% miconazole / 2% chlorhexidine; RCT-B randomised controlled 
trial – blinded.   
